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Abstract:  This  document  provides  first  insights  towards  a 
comprehensive  roadmap for  ethical,  legal  and socio-economic  (ELSE) 
aspects of facilitating the uptake of healthgrids in Europe. The roadmap 
is to be further developed by the end of the project. Based on a storyline 
model approach, relevant ELSE issues identified are discussed in detail 
and some generic recommendations are provided. 
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In D4.1 “Ethical, Legal, Socio-Economic Aspects of healthgrids: 
Baseline” [R1], we set out in some detail the existing EU level 
legal tools as well as economic principles that are important in 
understanding  the  potential  bottlenecks  for  healthgrids  in 
Europe. 
We began to explore legal issues that might affect the uptake 
and  deployment  of  healthgrids  in  the  EU,  in  particular 
legislation on Data  Protection,  on Liability  for  Goods  and on 
Services and Intellectual Property Rights. 
Legal  and  regulatory  issues  are  only  one  side  of  the  non-
technological  challenges  to  implementing  healthgrid  based 
solutions in Europe. Planning effectively to get the most out of 
this  technology  requires  a  thorough  understanding  of  the 
economic  and  social  drivers  that  impact  on  the  uptake  of 
healthgrids. D4.1 thus also began to look at the factors that a 
thorough healthgrid roadmap should take into account if it is to 
be effective in supporting further development and ultimately 
uptake of grid-based computing in the health sector.
We came to certain broad conclusions in our first deliverable:
• EU-level legislation on data protection is adequate but not 
ideal for promoting healthgrids. When healthgrids are used 
for  treating patients or planning care,  the requirements of 
the  legislation  provide  that,  if  the  data  are  collected  and 
processed  by  medical  professionals,  the  balance  of  rights 
weighs in favour of data collection. That is, it is assumed that 
the  patient’s  general  interest  in  obtaining  treatment  or 
advancing  medical  care  outweighs  his  interests  in  privacy. 
The current legislation is not, however, adequate to support 
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most of the longer running research initiatives around which 
healthgrids are based. 
• Our examination of the EU level legislation on  liability for 
goods and services showed that the legislation is not at all 
adapted to the healthgrid domain. One of the reasons for this 
is, of course, that health services are organised at national or 
regional  level  and  that  the  European  Union  has  no  legal 
competence  to  draw  up  legislation  that  states  specifically 
how a health service should be organised.1 However, the EU 
does have a range of legislation designed to protect citizens 
from harm resulting from goods offered on the market. Steps 
could be taken using guidelines, or even specific legislation, 
to  address  distributed  computing  services,  such  as 
healthgrids,  which  would  seem  at  present  to  be  only 
marginally  covered  by  the  existing  rules.  Accordingly  it  is 
important  the  existing  European  framework  of  general 
product safety is re examined to consider its applicability to 
distributed networks such as healthgrids. 
• There  is  a  question  as  to  whether  EU  legislation  on 
medical devices  applies to healthgrids. While it  may be 
argued that a healthgrid could fall within the ambit of the 
current Medical Devices Directive in that it is a software 
tool that impacts on a medical act, the whole construction 
of the Directive is based upon physical goods (which might 
have  a  software  component)  placed  on  the  market  for 
purchase or lease. The Directive is therefore ill adapted to 
deal with the shared domain of grid-based services where 
software sold and owned by a wide range of participants in 
a grid initiative.
• It would seem therefore that at present the only real way to 
have clarity over liability for the possible negative effects 
of healthgrids is through tightly constructed contracts in 
private law. 
• However,  to  move  healthgrids  beyond  the  domain  of 
university led and funded research tools we would need to 
address squarely the need to develop robust tools for sharing 
1  Treaty of  the European Union Art.  152 provides that  matters of  health  services organisation are 
subject to the rule of subsidiarity and limits the role of the EU to support and co-ordination.
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of  the  intellectual  property  inherent  in  the  design  and 
population of a healthgrid application.
• In  terms  of  economic  analyses,  we  identified  two  main 
issues affecting eHealth investments in general: the benefits 
are often non-financial,  which thwarts eHealth investments 
that should be made from an economical point of view; and 
many  potential  investors,  in  particular  healthcare  provider 
organisations, do not realise what the scope of the benefits to 
themselves might be.
• Ethical considerations run in the background of all of these 
issues: in the application of laws to healthcare systems, in the 
consideration  of  socio-economic  issues,  and  in  the 
organisational changes that might affect any relation with a 
patient.
Thus, in D4.1 we looked at the principles of healthgrids. The 
approach  to  D4.2  is  at  first  a  generic  one,  analysing  these 
principles  further  and  the  SHARE  vision,  and  exploring  the 
ELSE issues that will need to be considered and ‘dealt with’ if 
they  are  not  to  become  obstacles  or  roadblocks  to  the 
deployment and use of the technology.
This work includes a list of common challenges and bottlenecks 
from  the  baseline  reports  [R1  and  R2],  complemented  by 
drawing up an initial view of the appropriate response from the 
research community (see also R3). Based on a storyline model 
approach,  RTD  activities  to  address  these  issues  will  be 
structured into a first version of the ethical, legal, social and 
economic components of the roadmap.
The purpose of D4.2 is thus to begin to map the ethical, legal 
and  socio-economic  issues  onto  the  main  technological 
milestones (i.e., computing grid, data grid, knowledge grid), in 
order to build towards a comprehensive roadmap for healthgrid 
development in Europe. 
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1.2. APPLICATION AREA
The document is intended for internal and external use. It will 











This document will be updated incrementally via WP4 activity 
as new information becomes available.
Any comments or feedback should be sent to the authors.
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2. EXECUTIVE SUMMARY
The  objective  of  the  SHARE  project  is  to  map  key  RTD 
(Research and Technology Development) actions that need to be 
taken  at  EU level  to  focus  and  advance  healthgrid  solutions 
meeting the needs of European and global medical and health-
related  research,  health  policy  priorities,  and  of  healthcare 
providers, thereby supporting the delivery of safe, high quality 
health and social care to European citizens, and also meeting 
foreseeable future challenges. In this way the study will prepare 
the ground for improved uptake of healthgrid technology. 
Building  directly  on  the  ELSE  (Ethical,  Legal  and  Socio-
Economic  issues)  Baseline  Report  [R1],  this  deliverable 
identifies the key challenges in the development of healthgrid 
solutions  in  Europe from the perspective  of  ethics,  laws  and 
regulations and socio-economic questions, including those that 
may be an impediment to the full exploitation of the technology. 
In this deliverable, the ethical, legal and socio-economic issues 
begin to be mapped onto the technology roadmap [R3], building 
towards a comprehensive roadmap in WP6. 
While grid technologies are potentially of considerable added 
value  for  health  research,  the  SHARE vision  sees  healthgrid 
applications of use to a wide community of varied stakeholders, 
including  the  (software)  industry,  insurances/payers,  hospital 
management,  (inter)national  authorities,  clinical  professional 
organisations and the research community. In the long run, the 
list of stakeholders would extend to the patient, as healthgrids 
are  deployed  through  various  applications  into  medical 
practice. This deliverable, and the project in general, therefore 
seeks to go beyond ‘just’ the research community. Hypotheses 
of  potential  ELSE  roadblocks  on  the  way  of  healthgrid 
development  will  be  exposed  to  be  addressed  in  the  WP5 
application  test  cases,  which  will  model  the  use  of  grid 
technology  in  two  domains:  epidemiology  and  innovative 
medicine. 
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In  addition  to  potential  obstacles  and  barriers,  studies  on 
efficiency and improvement of care chains are also described, 
as  are  economic  and  financial  issues  (benefit/cost 
considerations). The potential of healthgrid solutions needs to 
be understood by a wide user community if the technology is to 
be sought, applied, and developed in a sustainable manner. In 
other  words,  it  is  important  to  consider  the  ‘pull’  for  the 
technology, and WP4 seeks to make the attractiveness of the 
technology  understood  by  a  wide  user  community  –  the 
language  of  this  deliverable,  as  well  as  that  of  other  WP4 
deliverables,  seeks  to  be  as  simple  and  non-technical  as 
possible, even when delving into complex issues of law, ethics 
and economics. 
The  healthgrid  roadmap  will  cover  the  domain  of  RTD  and 
uptake  of  grid  applications  in  healthcare  comprehensively, 
including infrastructure, security, legal, financial, economic and 
other policy issues.
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3.  ETHICAL, LEGAL & SOCIO-ECONOMIC ROADMAP – A 
GENERIC APPROACH
The approach to the SHARE ethical, legal and socio-economic 





Legal & Ethical Social Economic
(Intermediate) Results / Outcomes
Approach to Roadmapping





















Figure 1 A Generic Approach to Roadmapping
This  first  ELSE roadmap  aims  to  identify  the  relevant  legal, 
ethical,  social  and  economic  issues  as  well  as  possible 
methodological approaches (and the stakeholders involved) that 
could be approached in the uptake of healthgrids vis-à-vis these 
issues. In this way, we begin to map the ELSE issues on the 
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technology milestones, identified as follows in the Technology 
Baseline [R3]:
- MD1  (Milestone  Deployment  1),  called  “Computing 
grid”,  corresponding  to  the  successful  permanent 
deployment of computing grid nodes inside European 
medical research centres;
- MD2,  called  “Data  grid”,  corresponding  to  the 
successful  permanent deployment of  data  grid nodes 
inside European medical research centres;
- MD3, called  “Research K-grid”,  corresponding to the 
successful  permanent  deployment  of  knowledge  grid 
nodes inside European medical research centres;
- MS1  (Milestone  Standard  1),  called  “grid  DICOM”, 
corresponding to the production of a standard for the 
exchange of medical images on the grid;
- MS2,  called  “grid  EHR”,  corresponding  to  the 
production of a standard for the exchange of Electronic 
Healthcare Records on the grid.
These  milestones,  as  identified  by  the  SHARE  project  team, 
correspond to important steps forward in grid services offered 
to  the  medical  research  community.  Starting  from  services 
made available on the existing grid infrastructures, a persistent 
distributed environment for medical  research has to be built. 
This  environment  will  progressively  be  enriched  with  new 
functionalities as technology progresses. 
It  should  be  noted  that  these  milestones  reflect  the  current 
focus of the consortium team on grid infrastructure for medical 
research  and not  on healthcare  practice.  In  the former  case 
adoption of grids is less dependent on the evolution of EC legal 
regulations.
Based  on  these  first  milestones,  an  action  plan  on  how  to 
address these issues and the respective timeline to achieve the 
desired solutions can be developed. As reflected in the figure, 
the  use  of  the  roadmap  will  require  that  the  intermediate 
FP6­2005­IST­027694 PUBLIC  19 / 249
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, J. 
Herveg, V. Stroetmann, 
K. Stroetmann, A. 
Dobrev, C. Van 
Doosselaere, P. Wilson 
 
outcomes be analysed and the results fed back to adapting the 
objectives and actions correspondingly. 
WP4  begins  to  address  the  use  of  healthgrids  by  a  wider 
community, as reflected in part by the “healthgrid Story” (see 
Chapter  6).  In  the  baseline  report  and  in  its  first  roadmap, 
ELSE  issues  begin  to  pose  the  questions  that  will  require 
answers  as  healthgrid  technology  moves  from  an  internal 
research core to more widespread applications.
The findings from our Baseline Report are reflected and further 
developed  in  this  first  Roadmap  Report,  supported  by  a 
“healthgrid  Story”.  This  allows  issues  to  be  further  analysed 
and first insights into required actions to be gained. In a next 
stage,  this  will  be enhanced through an analysis  of  concrete 
successful  projects,  probably  Mammogrid  and  WISDOM,  and 
integration  of  parallel  research  and  analysis  within  other 
SHARE  Work  Packages.  In  particular,  this  will  be  the 
Technology Roadmap and Use Case Reports on Epidemiology 
and Innovative Medicines.
This process is illustrated in the following Figure :
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Figure 2 Developing the ELSE Roadmap – a Process View
To summarise, the following steps will be preformed to develop 
the basis for ELSE Roadmap I:
• Initial identification of subject topics, issues, processes
• Detailed  discussion  of  relevant  ELSE  issues  based  on  a 
“healthgrid Story”
• Generic recommendations.
In  a  next  step,  a  further  refinement  of  relevant  issues  will 
follow, combined with 
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• Analysis of concrete projects (e.g., Mammogrid, WISDOM)
• Identification of ELSE issues in the context of the two use 
cases – epidemiology and innovative medicines. 
For instance, in the case of epidemiology (D5.1a) the following 
specific constraints have been identified:
• Legal  regulations  restrict  the  storage  and  use  of  personal 
electronic data. 
• Obtaining  patient  consent  for  population-level  information 
could be unmanageable and encryption techniques for large 
population data inefficient and even fragile. Anonymisation2 
and data dissociation appear to be a more realistic approach. 
Other issues that must be resolved include:
• Traceability  of  accesses.  Access  to  personal  data  must  be 
traceable during the integration process and at least while 
the  private  information  has  not  been  removed.  This  is 
compulsory due to European and national regulations, which 
require identifying the potential leakages of privacy and the 
responsible persons.
• Management  of  patient  consent.  Requesting  a  patient’s 
consent must clearly outline the usage of the medical data for 
epidemiological studies.
• Traceability of pseudo-anonymised data. It must be possible 
for  the  data  subject  or  closely  related  persons  to  revoke 
permission  of  using  the  data  in  the  future.  It  is  therefore 
imperative to keep track of the modifications to the data. 
Finally, the results of this process will be integrated in a final 
deliverable (D4.3) – ELSE Roadmap II – and built into SHARE’s 
final deliverable, D6.2, the integrated roadmap.
2  Currently,  the law stipulates that  anonymisation is  the only way to ensure that  data are totally 
detached from the identity of the patient.  Pseudo-anomynisation does not entirely break the link 
between the information and the patient, in that it is always technologically possible to reverse the key 
used to pseudo-anonymise the data.
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4. THE HEALTHGRID VISION AND THE SHARE PROJECT
The  long  term  goal  of  healthgrids  is  to  offer  to  healthcare 
professionals  an  environment created through the sharing of 
resources, in which heterogeneous and dispersed medical data, 
as well as applications, can be accessed by different users as a 
tailored  information-providing  system,  depending  on  their 
authorisation,  and  without  loss  of  information.  Such  an 
environment should thus enable primary data and resources to 
be accessed differently (and correctly) by different users, while 
further allowing for secondary use of the data and access to the 
resources to the research community involved in medical & life 
sciences. 
The SHARE project  aims to  develop a  European roadmap to 
enable the realisation of this vision, looking in particular at the 
technology  developments  required  for  the  take-up  of  the 
technology. While the recent emergence of grid technology in 
the world has opened up new perspectives in interdisciplinary 
research  and  technology  development  at  the  crossroads  of 
medical  informatics,  bioinformatics  and  system  biology 
impacting healthcare, the potential for this technology is all the 
greater in the EU as Member States begin to face increased 
citizen mobility. There is thus an ever-increasing need for cross-
border  interoperability  of  data,  cross-border  infrastructures, 
optimal exploitation of resources (both technical and medical), 
and  definition  and  implementation  of  standards  in  order  to 
ensure  an  equitable  distribution  of  health  and  social  care, 
respecting  the  overarching  values  of  universality,  access  to 
good quality care, equity and solidarity as well as the operating 
principles upon Member States’ health and social systems are 
based  (quality,  safety,  evidence-based  care,  ethics,  patient 
involvement, redress, and privacy & confidentiality).
Grid technology responds to this need for pooled resources and 
sharing  of  geographically  distributed  data.  However,  as  with 
any  emerging  technology,  the  use  of  grid  also  poses  some 
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questions, especially when applied to such a sensitive field as 
that of medicine and health.
While the technical components of the SHARE project look at 
necessary  technology  developments  necessary  for  the 
deployment of healthgrids, the ethical, legal and socio-economic 
components of the project examine the questions that the use of 
these technologies might imply. What provisions does EU-level 
law  (with  its  application  at  national  level)  make  for  the 
processing of data, especially when it concerns such sensitive 
information  as  personal  details  and/or  health-related  data? 
From  an  ethics  perspective,  how  do  thousands  of  years  of 
medical practice change (or not) in the age of eHealth? In the 
face of increasing pressures and expectations, how can health 
systems  afford  to  invest  in  a  new  technology,  with  all  the 
organisational changes that implies? Can they afford not to do 
so? And practically speaking, what will these technologies mean 
for the end users: the health and social care professionals, and 
the  research  community?  How  will  they  do  their  work 
differently and how will this difference make their work easier 
or better? 
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5. STATUS QUO
5.1. ISSUES IDENTIFIED IN BASELINE AND 
FRAMEWORK REPORTS
5.1.1.Introduction
In our ELSE Baseline Report we have explored the relevant EU 
level legislation that may be said to have some impact on the 
use of healthgrid technology in the European healthcare field 
through a series of questions and answers. We have set out a 
number of social and economic issues impacting on healthgrid 
uptake and have also provided an introduction to fundamental 
principles  of  biomedical  ethics.  These  starting  points  are 
summarised below, before creating an initial catalogue of issues 
for further work.
5.1.2.Ethical issues in the use of healthgrids
In our Baseline Report, we introduced medical ethics, citing in 
particular Beauchamp and Childress’  Principles of Biomedical 
Ethics3 first  published  in  1979  and  now  in  its  fifth  edition 
(2001). In this book the authors set our four principle of ethical 





In order to revisit these points we consider briefly the extent to 
which  these  core  principle  may  pose  questions  for  the 
healthcare practitioner wishing to use a healthgrid application.
5.1.2.1.Autonomy and healthgrids
Autonomy is intimately tied up with the legal duties of consent 
and confidentiality.  Both however  could prove difficult  in  the 
context of healthgrids.
3  BEAUCHAMP, T. and CHILDRESS, J. Principles of Biomedical Ethics. Oxford University Press, USA; 5th 
edition (February 15, 2001)
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The  first  question  to  ask  therefore  is  whether  the  use  of  a 
healthgrid in the provision of care to a specific patient would 
require special consent. Looking at the example of the Oxbridge 
Cardiac Care grid  (See Chapter 5), we can see that the doctor 
intends  to  submit  the  patient’s  data  to  a  grid  application  in 
order to get assistance with the diagnosis. We will discuss later 
the need for consent to share the data in this way, but first must 
establish  if  the  use  of  the  grid  application  as  such  requires 
special  ethical  and  legal  consideration.  Here  the  question  is 
really one of the impacts the use of a grid-based tool has on the 
patient. Ethically we are looking at autonomy: is the patient’s 
autonomy  compromised  by  not  fully  understanding  the 
technologies  being  used  in  providing  care?  Generally  it  is 
accepted  that  if  a  doctor  uses  state-of-the-art  medical 
technology  in  the  conventional  way  then  a  patient,  in 
consenting to the care provided by that doctor, is consenting to 
the  use  of  such  technology.  Thus,  we  do  not  expect  a 
cardiologist  to  obtain  special  consent  for  using  an 
electrocardiogram (ECG), nor a radiologist for using magnetic 
resonance imaging (MRI). 
Two  caveats  should  however  be  observed.  If  the  technology 
could  create  harm to  the  patient,  special  consent  should  be 
obtained, since respecting autonomy means providing sufficient 
information  so  that  the  autonomy  of  the  ‘informationally’ 
weaker party can be exercised. Thus, the risks of an epidural 
anaesthetic  must  be  explained  before  the needle  is  inserted. 
The  same  argument  exists  if  the  risk  is  social  rather  than 
medical.  Thus  testing  for  a  genetic  condition  that  is  not 
amenable to treatment requires prior consent since knowledge 
of possessing such a gene will be a burden to the patient and 
might also affect rights to social goods such as health insurance 
and mortgages.
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For us then the question is if the use of a grid application per se 
falls  into  these  special  categories.   We  would  propose  two 
guidelines here:
1) If the use of a grid based tool is simply a way of getting 
a  more  complete  diagnosis  and  moreover  if  it 
constitutes a reasonable use of medical expertise then 
no special consent would be ethically required;
2) If  the  use  of  the  grid  based  tool  could  expose  the 
patient to any risks such risks must be disclosed and 
special consent would be required.
We  can  see  thus  that  the  extent  to  which  the  grid  poses  a 
special ethical problem is not around consent to the use of the 
technology itself, but rather in consent to the sharing of medical 
information in the context of the duty of confidentiality. 
The legal requirements of confidentiality have been extensively 
discussed in the Baseline on Ethical, Legal and Socio-Economic 
Issues [R1]. Here we look at the ethical aspects of that duty. If 
submitting a patient’s information to a grid based application in 
any way might allow other people to identify the patient, his or 
her autonomy is compromised. 
Thus in healthgrids, one of the key ethical issues will be in the 
possible compromise of the patient’s autonomy that will arise 
from sharing his  or her data  with  people  who are yet  to be 
identified. It is worth noting that it has been argued, notably by 
the European Article 29 Data Protection Working Party4,  that 
consent has only a very limited place as a justification of the 
sharing  of  health  related  data  in  the  electronic  age.  The 
Member  States’  data  protection  commissioners  note,  with 
particular  reference to  the development  of  Electronic  Health 
Records systems that seeking a patient’s consent to the sharing 
of information is  not easily  justified when to do so would be 
asking the patient to opt for a lower quality of care. They argue 
therefore  that  robust  system  of  security  of  information  and 
4  Article 29 Working Group on Data Protection. Working Document on the processing of personal data 
relating to health in electronic health records (EHR), WP131.
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ethical practice should be adopted in which patients will be able 
to trust, notwithstanding that their information is shared, and 
providing for special opt-out possibilities when the nature of the 
information is especially sensitive.
In the development of healthgrids, we must therefore develop 
good ethical guidelines on how to share information, including 
the  use  of  anonymisation  and  pseudonymisation  wherever 
possible as well as general information campaigns which will 
make patients more aware of the way their information may be 
shared so that if they feel the need to do so they will know when 
and how to refuse to allow such sharing to take place. 
5.1.2.2.Beneficence and Non-Malfeasance
As  the  Oxbridge  Cardiac  Care  grid  case  explores,  the 
importance of the application lies in supporting the healthcare 
professional’s decision so that he or she may be better equipped 
to do good and avoid doing harm. As such, one could thus argue 
that a healthcare professional, in acting ethically, would indeed 
be  obliged  to  use  suitable  grid  applications  if  they  were 
available.  A  healthcare  professional  refusing  to  use  standard 
medical technology such as a sphygmomanometer or refusing to 
prescribe antibiotics would be considered in breach of his or 
her duty of beneficence, thus, as the sophistication of grid aided 
diagnosis  develops  we will  one  day  arrive  at  a  time when a 
healthcare  practitioner  not  linked  to  the  appropriate  grid 
networks will be in breach of his or her duty.
However, until we have reached a time when grid applications 
are  stable,  well  ‘fed’  with  data  and fully  integrated  into  the 
evidence base of good clinical practice such arguments will not 
apply.  At  present,  in  the  more  experimental  stages  of  the 
healthgrid it  will  be important to ensure that  the use of  the 
applications  does  no  harm,  but  perhaps  most  importantly  to 
ensure that the patient is aware of any possible medical and 
social  risk  (such  as  breach  of  confidentiality)  so  that  the 
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applications  can  continue  to  develop  without  allegations  of 
breach of ethical duties.
5.1.2.3.Justice
The  ethical  principle  of  justice  concerned  with  the  duty  to 
achieve a fair distribution of resources as well as the need to 
develop an overall  just  medical  system in which the greatest 
health of  the greatest  number is  achieved is  the principle of 
justice. It is in the respect for this principle that the greatest 
potential ethical benefit of healthgrids lies. The developments of 
applications  such  as  Mammogrid  have  established  that  the 
sharing of a very large number of mammogram images across a 
wide  network that  allows  radiologists  to  test  suspect  images 
against  a  known  and  tested  database  of  cases  significantly 
contributes  to  the  early  detection  of  breast  cancer.  The 
healthgrid in this case not only acts to the benefit of the known 
patient whose suspect image is submitted to the tool, but to the 
overall health of the population.
It can be seen therefore that healthgrids pose many challenges 
on an ethical level, as well as on a practical legal level. It is of 
great  importance  therefore  that  research  roadmaps  for 
healthgrids provide not only for scientific development but also 
for  social  science  research,  which  will  allow  us  to  further 
explore the extent to which the use of healthgrids can empower 
healthcare  professionals  to  meet  their  four  cardinal  ethical 
duties of respecting autonomy, doing good and contributing to 
the justice in healthcare.
5.1.3.Legal Issues in the use of healthgrids
As  described  in  the  ELSE  baseline,  legal  issues  include 
legislation concerning Data Protection, Liability for Goods and 
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Services and Intellectual Property Rights. The socio-economic 
treatment  of  the  topic  deals  with  the  wider  social  values  of 
health and health systems and the key actors with social and 
economic interests in such systems. 
In  this  section  we present  a  brief  overview of  the  key  legal 
issues as outlined in the baseline. A full discussion on all the 
relevant EU level legislation is found in the three annexes to 
this report.
Looking back at the discussion on Data Protection5, we can see 
that in broad terms the current EU level legislation is adequate 
but not ideal for promoting healthgrids. When healthgrids are 
used  for  treating  patients  or  planning  care,  the  balance  of 
rights weighs in favour of data collection - that is, it is assumed 
that  the  patient’s  general  interest  in  obtaining  treatment  or 
advancing  medical  care  outweighs  his  or  her  interests  in 
privacy. 
The  current  legislation  is  not,  however,  adequate  to  support 
most of the longer running research initiatives around which 
healthgrids  are  based.  As  the  current  EU  level  legislation 
stands, Member States can enact specific legislation covering 
specific tools such as healthgrids in order to exempt scientists 
and medical practitioners using healthgrids from some of the 
more onerous duties of the Directive. 
No Member State has addressed legislation to this particular 
issue  and  so  healthgrids  are  burdened  with  onerous  data 
protection requirements which could deter scientists from using 
adopting  healthgrid  technology  and  using  its  enhanced 
computational and data acquisition power.
5  For  a  detailed  legal  analysis  of  the  data  protection  issues,  please  see Annex  I  to  this  document 
dedicated to Data Protection, Confidentiality and Security Issues.
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EU level legislation on Liability for Goods and Services is not at 
all adapted to the healthgrid domain6. One of the reasons for 
this is, of course, that health services are organised at national 
or  regional  level  and  that  the  European  Union  has  no  legal 
competence to draw up legislation that states specifically how a 
health service should be organised7. 
However, the EU does have a range of legislation designed to 
protect citizens from harm resulting from goods offered on the 
market. Steps could be taken using guidelines, or even specific 
legislation, to address distributed computing services, such as 
healthgrids that would seem at present to be only marginally 
covered by the existing rules.  Accordingly it is important that 
the existing European framework of general product safety be 
re-examined to consider its applicability to distributed networks 
such as healthgrids.
Furthermore the law on medical devices is very unclear with 
respect to healthgrids: while it may be argued that a healthgrid 
could  fall  within  the  ambit  of  the  current  Medical  Devices 
Directive in that it is a software tool that impacts on a medical 
act,  the  whole  construction  of  the  Directive  is  based  upon 
physical goods (which might have a software component) that 
are placed on the market for purchase or lease. The directive is 
thus ill adapted to deal with the shared domain of grid based 
services  where software sold and owned by a  wide range of 
participants in a grid initiative.
It  would seem therefore that at present the only real way to 
have clarity  over  liability  for  the possible  negative  effects  of 
healthgrids is through tightly constructed contracts in private 
6  For a detailed legal analysis of the liability issues, please see Annex II to this document dedicated to 
liability issues in the use of healthgrid technologies.
7  Treaty of  the European Union Art.  152 provides that  matters of  health  services organisation are 
subject to the rule of subsidiarity and limits the role of the EU to supporting and co-ordinating the 
activities of the Member States.
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law.  If  however  the  use  of  healthgrids  across  EU  and 
international  borders  in  shared  public/private  initiative  is  to 
become  a  reality  then  steps  should  be  taken  to  develop 
guidelines  and  possibly  legislation  to  harmonise  the  legal 
expectations of all actors in a healthgrid. As an interim step to 
EU legislation in this area it could be suggested that a suitable 
body,  such  as  the  High  Level  Group  on  Healthcare,  be 
established.
However, to move healthgrids beyond the domain of university 
led  and  funded  research  tools  we  would  need  to  address 
squarely  the need to  develop  robust  tools  for  sharing of  the 
intellectual property inherent in the design and population of a 
healthgrid application.
As  the  law  currently  stands  the  rules  of  copyright  are  very 
protective  and  could  constitute  an  impediment  in  the 
implementation  of  healthgrids  because  they  treat  computer 
software as a copyrightable literary work, the same as a play or 
a novel8. 
Currently,  the  owner  of  the  copyrighted  software  running  a 
healthgrid  has  the  exclusive  rights  to  reproduce  his  work, 
prepare  derivative  works,  distribute  copies  to  the  public, 
perform the work publicly and display the work publicly. Under 
these circumstances any natural or legal person would have to 
pay to use computer programs while they constitute one of the 
most important compounds of healthgrids. Given that most grid 
applications  will  depend  on  shared  access  to  multiple-
copyrighted  programmes  it  is  unlikely  that  such  a  model  of 
copyright  is  useful  in  protecting the entirety  of  a  healthgrid 
application. 
8  For a detailed legal analysis of the intellectual property rights implied by the implementation of grids, 
please see Annex III to this document.
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An open standards approach to software co-development could 
help the development and implementation of healthgrids. The 
open  source  licensing  model  actually  uses  copyright  and 
contract principles to retain control of the work while enabling 
its use effectively for free and could thus encourage use and 
development.
5.1.4. Socio­economic issues in the use of healthgrids











From   a  socio­economic   perspective,   it   becomes   obvious   that   the   uptake   of 
healthgrid systems and solutions will also heavily depend on the extent to which 
they can help address problems and challenges of health systems9. Such impact is 
presumed, yet  there is  little evidence of  its scope. Detailed analysis of existing 
applications, as well as ex­ante assessments of the benefits from the future use of 
healthgrids will be essential for mobilising the required will and enthusiasm among 
research   funding   entities,   political   organisations  and  society   at   large.  Potential 
benefits   include   timesavings,   particularly   important   in   cases   of   potential 
pandemics,   and  access  to   better   quality   clinical   and  research   data,   leading  to 
improvements in the quality of clinical outcomes. The methodological framework 
9  A comprehensive treatment of the subject of health systems challenges in forthcoming in a report to 
the “Scenarios4Health - Scenarios for ICT-Enabled New Models of Health Care” project (IST- 150644-
2006-F1SC-DE), http://www.scenarios4health.eu/
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The  same  framework  can  also  be  used  as  the  basis  for 
addressing  another  inhibitor  to  a  widespread  adoption  of 
healthgrid  solutions  –  lack  of  (knowledge  about)  private 
incentives.  A  business  case  for  the  routine  use  of  grid 
technologies in the health sector is essential for moving from 
project-based, exemplary utilisation to a widespread uptake of 
healthgrid based solutions. As has been acknowledged by the 
literature10,  private  incentives  play  an  important  role  in 




the   macro   level.   Both   at   the   individual   and   the   societal   level,   issues   like 
universality of availability of full healthcare services to all citizens, equal access to 









10  for  example,  see  ETTNER,  S.L.and  M.  Schoenbaum.  “The  role  of  economic  incentives  in 
improving the quality of mental health care”, in ed. JONES, A.M. “The Elgar Companion to Health 
Economics”, Edward Elgar Publishing, 2006
11  “Council Conclusions on Common values and principles in European Union Health Systems”, 
Document (2006/C 146/01), Official Journal of the European Union on 22 June 2006, pp. 1 - 5
12  STROETMANN, K.A. JONES, T. DOBREV, A. and STROETMANN, V.N. “eHealth is Worth it - 
The economic benefits  of implemented eHealth solutions at ten European sites”, Office for Official 
Publications  of  the  European  Communities,  Luxembourg,  2006  (56  pp.  -  ISBN  92-79-02762-X), 
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• Increased  collaborative   working   and   exchange   of   information   between 
providers








globalisation   of   healthcare   services).   Looking   at   another   dimension   of 
organisational   issues, work   flow/process  organisation will   equally   be   impacted 
upon. 






available on  www.ehealth-impact.org; “Scenarios4Health: Scenarios for ICT-Enabled New Models of 
Health Care”, forthcoming on http://www.scenarios4health.eu/
13  MANNION, R.  DAVIS,  H.T.O.  and M.N. MARSCHALL “Cultures  for  Performance  in  Health 
Care”, Open University Press, 2005
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• Data Protection (legitimacy, multiple data controllers, 
medical and non-medical access, quality of data, secur-
ity and confidentiality, data subject’s rights, transfer of 
personal data outside of the European Union, etc.)
• Liability  for  Goods  and  Services  (use  of  automated 
decision support in health service provision...)
• Intellectual  Property  Rights  (healthgrid  operating 
systems,  applications  and  models,  collections  of 
medical data, etc.)
An initial list of economic issues is as follows:
• Cost-benefit and cost-utility analysis
• Benefits  to  patients,  professionals,  organisations  and 
health systems
• Costs  to  patients,  professionals,  organisation  and 
health systems
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Finally, social issues include:
• Organisational inertia and change management
• Training, education and new skills requirements
• Collaborative  working,  new  relationships  and 
partnerships
• Cross-organisational resource deployment
• Process design and new care pathways
• Acceptance and culture of healthcare professionals
• Trust and confidence (automated decision support)
• Awareness and understanding 
• Leadership and political support
• Policy development
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6. A STORY MODEL APPROACH
In our Legal and Economic Framework Report we have set out, 
in some detail,  all  EU level  legislation which may be said to 
have some impact on the use of healthgrid technology in the 
European healthcare  field.   To  draw together  the key  issues 
highlighted and set out an inventory of potential bottlenecks we 
look at the issues once more in the context of a case vignette. 
The story outlined below14 shows some of the potential uses of a 
healthgrid application in daily healthcare delivery and outlines 
the  way  in  which  the  current  European  level  legislation 
responds to the issues. The intention here is to go beyond the 
SHARE  technology  roadmap  goal  focusing  on  a  grid 
environment  predominantly  for  medical  research,  and  to 
elaborate on potential  impact not only for applying improved 
and  new  methods  for  diagnosis  and  treatment  but  also  for 
routine trans-border, pan-European patient data exchange.
The story is presented twice below, once as a simple narrative, 
and once with key words highlighted and assessed for ethical, 
legal, social and economic issues.
Using  the  list  of  potential  economic  and  legal  bottlenecks 
highlighted by the story, and drawing also on more established 
applications such as WISDOM and Mammogrid, we present a 
roadmap of EU and national level actions necessary to support 
and accelerate the development and implementation of healthgrids 
in Europe.
6.1. A HEALTHGRID STORY OF TOMORROW
The  following  is  a  fictional  episode  from  day-to-day 
medical  practice  showing  a  conventional  response  to  a 
condition at the point of care:
It’s  a  busy  morning  surgery  at  a  Madrid  family 
practice  when  Dr.  Maria  Hernandez  sees  a  pale 
14   Adapted from KNIGHT, W. “Wear your heart on the screen”. The Guardian, Thursday April 27, 2006. 
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clammy  50-something  man,  Mr.  Sanchez, 
complaining of chest pain. An ambulance is called 
immediately.  “I  treat  it  as  a  heart  attack  until 
proven  otherwise,”  she  says.  “It’s  protocol,  and 
coronary  heart  disease  (CHD)  is  the  commonest 
cause of chest pain in middle-aged men. It’s also the 
commonest reason I call an emergency ambulance. 
It happens frequently.” In preparation for Sanchez’s 
arrival operating theatre staff are mobilised and the 
theatre  reserved;  the  tests  carried  out  in  the 
ambulance and on admittance are not conclusive so 
that what follows is an expensive hospitalisation and 
with a high probability of risky medical intervention.
Here is an alternative story:
It’s  a  busy  morning  surgery  at  a  Madrid  family 
practice  when  Dr.  Maria  Hernandez  sees  a  pale 
clammy  50-something  man,  Mr.  Sanchez, 
complaining of chest pain. She calls an ambulance. 
“I still have to treat it as a heart attack until proven 
otherwise,” she says. Dr. Hernandez explains to her 
patient that she would like to refer his case to her 
heart  specialist  colleagues  in  Oxbridge,  UK.  The 
Oxbridge  group,  in  collaboration  with  institutions 
around  the  world,  has  already  uncovered  many 
secrets  of  this  vital  organ  without  opening  up 
patients or running dangerous drug trials. They are 
creating  a  heart  on  a  computer  -  a  model  -  and 
subjecting it to all the stresses of modern life and 
watching  how  it  responds,  which  is  called  the 
Oxbridge  Cardiac  Care  grid  (OXCCG).  The  model 
runs on healthgrid infrastructure.
As she places the ECG leads on Mr. Sanchez,  Dr. 
Hernandez  points  out  how  this  model  allows 
researchers  to  delve  into  the  heart  and  witness 
events that are impossible to see without dangerous 
surgery. “You can see the outside of the heart, but ... 
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it’s very difficult to get data from the inside,” she 
says. She goes on to explain “the real beauty is that 
the  complicated  computing  is  hidden  from  the 
scientist.  The  researchers  submit  code  though  a 
portal  interface.  It  puts  all  the  data  in  the  right 
place and pulls it back when you need to do things 
with  it.  The  model  of  a  patient’s  heart  can  be 
constructed very rapidly, making the day-to-day life 
of  scientist  a  lot  easier  and  providing  an 
increasingly  valuable  service  directly  into  clinical 
diagnostics.  Scientists  want  to  focus  on  the  life 
science  and  clinicians  need  rapid  results  without 
having  to  think  about  how  these  big  machines 
work.”
The Oxbridge colleagues use the spare computing 
capacity  of  a  large  number  of  computers  across 
Europe, including that of Dr. Hernandez, to conduct 
this scientific modelling. The results of this in silico 
modelling  have  recently  become available  for  use 
directly  in  day-to-day  clinical  practice,  and  the 
harnessing of the enormous power of thousands of 
modern  computers  simultaneously  allows  a  very 
rapid diagnostic response.
On the basis of the in silico modelling conducted by 
colleagues  at  Oxbridge  Dr.  Hernandez  is  able  to 
diagnose  that  Mr.  Sanchez  in  fact  has  a  minor 
congenital abnormality and is not at risk of acute MI 
(myocardial infarction – “heart attack”). She cancels 
the  emergency  admittance  and  operating  theatre 
preparations and informs and treats him instead for 
the mild chest infection that had caused the pain 
with which Mr. Sanchez originally presented. On the 
basis of data received from academic colleagues she 
is able also to inform Mr. Sanchez fully about the 
benign congenital heart defect.
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Mr.  Sanchez  was  so  pleased  that  he  managed  to 
avoid a serious medical intervention on the basis of 
the advice his doctor got thanks to the healthgrid 
solution that he decided to write to the Minister of 
Health about the wonders of this new technology. 
He wrote, “It’s not about arguing if there is a cost 
benefit that will pay off for the health of the nation. 
The question is simply one of making industry and 
government organisations aware of the possibilities. 
It’s  time we made all  our  doctors’  and scientists’ 
computers act as one giant computer, and put them 
to work for the patients. It doesn’t even have to cost 
a  fortune  since  they  will  just  be  sharing  their 
collaborator’s resources.”
6.2.  A HEALTHGRID STORY – ETHICAL, LEGAL, SOCIAL 
AND ECONOMIC ISSUES HIGHLIGHTED
6.2.1.Ethical and legal issues
6.2.1.1.Cross-Border Referral 
Dr. Hernandez explains to her patient that she can  refer his 
case to her colleagues in Oxford, UK who, in collaboration 
with  institutions  around  the  world,  is  slowly  uncovering  the 
secrets  of  this  vital  organ  without  opening  up  patients  or 
running dangerous drug trials. They are creating a heart on a 
computer -  a  model -  and subjecting it  to all  the stresses of  
modern life and watching how it responds,  which is called the 
Oxbridge Cardiac Care grid (OXCCG)
In the story we see that Dr. Hernandez refers Mr. Sanchez’ case 
to colleagues in Oxbridge running the Oxbridge Cardiac Care 
grid This means she is seeking advice on a Spanish patient from 
someone in another European Union country, is this legal and 
ethical? 
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Before even thinking about whether Dr. Hernandez can legally 
send Mr. Sanchez data to Oxford to obtain a second medical 
opinion, we should establish that Dr. Hernandez is processing 
his data legally. If this processing forms part of a filing system 
or is intended to form part of a filling system it will be covered 
by  the  Spanish  Data  Protection  Legislation  enacted  in 
pursuance of the European Data Protection Act. Given that the 
medical records must be filed in some way, this would seem to 
be very likely, furthermore, If any automatic processing is used, 
such as and Electronic Health Record, then the rules of data 
protection will apply regardless of the nature of the processing.
We can assume that the processing of personal data is carried 
out by Dr. Hernandez is for the medical care and diagnosis of 
her registered patients. Accordingly such processing is covered 
by the rules concerning medical  data and does not need the 
explicit consent of the patients if the processing is made by a 
health  care  professional  subject  under  national  law  or  rules 
established by national competent bodies to the obligation of 
professional  secrecy or by  another person also  subject  to  an 
equivalent  obligation  of  secrecy  (ex.  secretary  or  assistant). 
Thus, although it is ethically correct that she has explained to 
Mr. Sanchez that she intends to send his data to Oxford she is 
not legally required to do so if she can ensure that the person to 
who the data will be sent is subject to a legal duty of secrecy. 
However, Dr. Hernandez, acts as data controller, has a duty to 
inform her  patients  generally  about  the  data  processing  she 
performs  or  others  perform  for  her  and  to  notify  that  data 
processing  to  the  relevant  national  supervisory  authority.  Dr. 
Hernandez  must  therefore  ensure  that  the  data  held  are 
adequate (accurate) and that they are held securely and that 
confidentiality is respected.
As medical data have to be processed by a health professional 
subject  under  national  law  or  rules  established  by  national 
competent bodies to the obligation of professional secrecy any 
processing of data is conducted by staff other than health care 
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professionals,  such  as  administrative  staff,  would  have  to  be 
under  a  contractual  or  a  legal  duty  of  confidentiality  which 
could  result  in  termination  of  employment  if  confidentiality 
were  broken.  A  policy  access  to  the  medical  files  should  be 
created. 
Thus we see that Dr. Hernandez has a legal right to collect and 
process  the medical  data  of  her patients  in order to  provide 
them with medical care. 
Now, however, she wishes to communicate her patients’ medical 
files to a third party, the Oxford University Cardiac Care grid 
(OXCCG) in order to provide her with decision support in order 
to better treat Mr. Sanchez.
Here we come to several legal and ethical questions. From a 
data protection perspective the first question to ask is whether 
such an operation on the patients’ medical data is compatible 
and necessary with the initial purpose of the data processing by 
Dr. Hernandez to provide the patients’ with medical care. Here 
Dr. Hernandez would need to show that the OXCCG allows her 
to  give  better  care  to  her  patients  and  therefore  may  be 
considered as necessary for the purposes of medical diagnosis 
and the provision of care or treatment. 
The next question to address is how the sharing of Mr. Sanchez 
medical  data  with  OXCCG  should  occur.  Here  it  will  be  a 
question of how the OXCCG works. If the services of OXCCG 
could be provided on the basis of Mr. Sanchez’ anonymised data 
then  Dr.  Hernandez  should  perform  the  necessary 
anonymisation and send only the anonymised data. It is unlikely 
however  that  this  will  be  the  way  in  which  OXCCG  works, 
because it is intended to provide Dr. Hernandez with patient-
specific advice. Although on a technical level it is possible to 
render such data anonymous, it is very difficult to satisfy the 
legal  rules  for  such  anonymity,  indeed  some  national  Data 
Protection authorities do not accept the concept of medical data 
anonymisation at all.
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Accordingly  Dr.  Hernandez  will  have  to  ensure  that  OXCCG 
process and store all identifiable data according to the law, that 
such data are processed only by people with a legal obligation 
of secrecy and that data are not held for longer than necessary. 
Dr. Hernandez would be well advised to have a legal contract 
between herself and OXCCG setting out these requirements. Dr. 
Hernandez  should  use  the  standard  contractual  clauses  as 
provided  by  the  Data  Protection  Directive  to  ensure  an 
adequate level of protection. 
If  the  OXCCG  runs  a  portal  accessible  by  registered 
practitioners any one of whom could see Mr. Sanchez record, it 
would be advisable to have the express written consent of the 
patient who confirms having been thoroughly informed about 
OXCCG processing and the access regime. 
It can be seen therefore that from a Data Protection perspective 
the submission of a named patient’s data to a healthgrid could 
be legally and ethically justified. It is established that so long as 
the data collected and processed by medical professionals, in a 
way necessary for the purpose of providing healthcare to that 
same patient,  the  balance  of  rights weighs in favour of  data 
collection  -  that  is,  it  is  assumed  that  the  patient’s  general 
interest  in  obtaining  treatment  or  advancing  medical  care 
outweighs his interests in privacy. 
However,  many  newly  developed  healthgrid  applications 
currently running are not designed primarily to be used in care 
delivery to an individual patient but for different, longer term 
purposes  –  that  is  research,  preventative  medicine  or 
healthcare planning. In addition, these applications are usually 
not  controlled  by  medical  professionals  but  by  research 
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scientists. Furthermore, for the purposes of research, a great 
deal of data is stored per patient including an extensive medical 
history. This makes it a practical impossibility to render the data 
set anonymous. Where this is the case, Member States have the 
possibility  to enact  specific  legislation covering specific  tools 
such as healthgrids in order to exempt the scientist using running 
healthgrids from some of  the  more  onerous  duties  of  the  Data 
Protection Directive. 
Member States could, for example adopt specific legislation to 
encourage the linking of diagnosis-specific databases across a 
region  or  state  in  order  to  support  research  into  a  given 
disease.  However,  to  date,  no  Member  State  has  specifically 
addressed  legislation  to  this  particular  issue.  In  this  legal 
environment,  healthgrids drawing the data  and data  processing 
power of many hospitals together are burdened with heavy data 
protection  requirements  which  could  deter  scientists  from 
adopting  healthgrid  technology  and  using  its  enhanced 
computational and data acquisition power.
Perhaps more significantly little attention has been paid to the 
specific  needs  of  data  sharing  for  healthgrids across  European 
borders and outside the Union. If healthgrids are really to grow to 
their full potential and deliver their promise adjustments must 
be made to national and supranational legislations to re-assure 
would-be healthgrid users that it is legal to share health related 
data using grid technology. This in turn implies the development 
and adoption of robust guidelines developed specifically for the 
healthgrid context and that address the balancing of interests 
between an individual’s privacy and medical advancement.
6.2.1.2.Reliance on an automated system – liability
She goes on to explain “the real beauty is that the complicated 
computing  is  hidden  from  the  scientist.  The  researchers 
submit code though a portal interface. It puts all the data 
in the right place and pulls it back when you need to do 
things with it. It's making the day-to-day life of the scientist a  
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lot easier. Scientists want to focus on the life science without 
having to think about how these big machines work."
Dr.  Hernandez  explains  the  potential  benefit  of  the  OXCCG, 
saying that researchers submit code to a portal which pulls the 
right data together at a time she needs in order to help her 
make  a  diagnosis.  We  have  already  looked  at  the  data 
protection issues here and have argued that special contracts 
will  need to be put in place to ensure that the possessing of 
medical data by a third party is legal.
Dr.  Hernandez’s  explanation  suggests  however  that  the  next 
level  of  interaction  she  has  with  the  OXCCG  is  based  on 
automated  data  retrieval  and  aggregation.  She  is,  in  effect, 
making a medical diagnosis on the basis of a machine decision.
Legally  this  poses  only  small  problems  as  long  as  no 
misdiagnoses are made. However, at a European level there is 
currently  no  legal  guideline  on  how  the  liability  should  be 
shared –  accordingly  this  is  currently  all  subject  to  carefully 
drafted  contracts  which  pre-define  liability  for  possible 
mistakes.  It may be argued therefore that the European Union 
should adopted either secondary legislation such as a Directive 
or  at  least  common  contractual  guidelines  for  clarifying  the 
cross border implication for shared care.
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6.2.1.3.Cross-border  and  cross-institutional  Licensing, 
IPR sharing
It’s  time  we  made  all  our  doctors’  and  scientists’ 
computers act as one giant computer, and put them to 
work for the patients. 
This sentence that Mr. Sanchez writes to his Minister of Health 
describes a situation that might sound ideal, but legally it would 
in fact be rather difficult to set up.
If it appears that legally the rights of the patient and the copy-
right the scientist will acquire on the database he created can 
coexist,15 in practice a conflict may occur, especially between 
patients’ rights and the personal data protection regime on one 
hand and the  sui generis rights protecting a database on the 
other hand. 
It may be argued that  the patient’s rights to the protection of their 
sensitive  data are superior to the copyright of  the scientists, 
which would have a direct impact on the exercise of authors’ 
exclusive rights. In law the scientists, here legally the authors, 
could not prohibit to the patient the access to and the use of a 
copy of his medical record, since this is a right accorded the 
patient through Data Protection law. Thus, the authors (here the 
copyright  owners)  could  not  exercise  their  exclusive  rights 
alone. Consequently  the  authors  could  not  protect  their 
15   To this extend see Recital  41 of the Directive 95/46/EC which states that “(..) this right must not 
adversely affect trade secrets or intellectual property and in particular the copyright protecting the 
software”.  On the other hand, Recital 48 of the Directive 96/9/CE states that  “ (…) the provisions of  
this Directive are without prejudice to data protection legislation”.  These texts show well that the 
European legislator had and still has some fears that one right might encroach on the other or that one 
of them might prevent the exercise of the other. It could be argued that, had the coexistence between 
both rights been easily made in practice, this cross-referencing in the text of the directives would not 
have been made. 
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interests in the databases and thus could not protect their work 
in the development of healthgrids.
 
On  the  other  hand,  there  is  a  contradiction  between  the 
intellectual  property  rights  and  the  needs  of  the  grid 
technology, which would require that the access to databases 
and to programs of computer is free of rights.
The challenge for EU and/or national legislators is therefore the 
find a way of balancing the two competing sets of rights - for if 
they do not a full exploitation of grid technology in healthcare 





development and implementation of healthgrids.  In  the United States,  the open 
source model   (being  a  more  open  system  than open  standards)  currently   uses 
copyright  and contract principles  to   retain control  of  the work and could  thus 
encourage use without dedicating the work to the public domain.16 Such a model 
could be adopted and developed into appropriate legal tools at the European level.
16  See KENNEDY, D.M. “A primer on open source licensing legal issues: copyright, copyleft and 
copyfuture, 20 ST. LOUIS U. PUB. L. REV., 2001, 345, p. 359-360; MCGOWAN, D. “Legal implications of 
open-source  software”,  U.  ILL  .L.  REV.,  2001,  241,  p.242-243.  More  generally  see  Open  Source 
Initiative, at http://www.opensource.org.
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Mr. Sanchez was so pleased that he managed to avoid a serious 
medical intervention on the basis of the advice his doctor got  
from her colleagues that he decided to write to the Minister of  
Health about the wonders of this new technology. He wrote "It's 
not about arguing if there is a cost benefit that will pay off 
for the health of the nation.
Mr. Sanchez’s statement relates to a crucial issue regarding the 
economic rationale for investing in deployment of Healthgrids – 
the distinction between private and social benefits.
In a market setting it is usually the main beneficiary of a service 
who pays, and investments are only made if adequate returns 
accrue  to  the  party  making  the  investment17.  In  healthcare, 
flows  of  benefits  may  diverge  from flows  of  costs.  "Private" 
benefits  to  investors  may  not  provide  sufficient  incentive  to 
invest  in  healthgrid,  even  though  benefits  to  society  may 
constitute a very substantial return. 
From the perspective of Mr. Sanchez, the cost benefit argument 
is indeed obvious and does not require lengthy discussions – he 
has  benefited greatly  from the use of  healthgrid  at  no extra 
cost.  Of  course,  this  is  not  the  same  for  all  stakeholders 
involved.  The  costs  and  benefits  for  Dr.  Hernandez,  and  in 
particular the difference between them, are less clear. She can 
17  See ANDERSON, G. F.  et. al., "Healthcare Spending and the use of Information Technology in 
OECD countries" in Health Affairs,  Volume 25, Number 3, May/June 2006
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only access the results from the healthgrid research at some 
cost,  be  it  direct  payment,  giving  access  to  her  computing 
capacity,  time  for  implementing  the  service  into  her  work 
process,  or  a combination of these.  Benefits  may range from 
personal satisfaction to financial benefits. The people running 
the  OXCCG  face  a  completely  different  challenge  –  the 
investment in OXCCG build up and maintenance is their main 
cost.  Their benefits  from using the results as physicians,  the 
same  way  as  Dr.  Hernandez,  are  unlikely  to  cover  the 
investment costs.
This  illustrates  the  complexity  of  the  cost  benefit  argument 
when  looked  upon  from  the  perspective  of  different 
stakeholders. When we turn to the so-called social benefits, i.e. 
benefits to society, the relevant items to consider will change 
again. The position of a policy maker, whether on Member State 
or EU level, should be that of a “social planner”. So from their 
perspective, it is important to know whether healthgrids “will pay 
off for the health of the nation”.
Different business organisation models for healthgrid services 
are  possible  and  an  important  step  towards  deployment  is 
choosing one in which private cost benefit ratios do not prove 
prohibitive  to  services  worthwhile  from the  point  of  view  of 
society.
Part  of  the  relevant  analysis  should  be  concerned  with  the 
distinction between financial and economic costs and benefits. 
Recent research18 shows that benefits from eHealth are often 
not  cash.  This  makes  achieving  sustainability  of  investments 
even more difficult. Private investments decisions are made on 
the basis of the expected rate of financial return. This is not 
always guaranteed, especially when the benefits are quality of 
care  or  cost  avoidance  for  extra  health  services.  Voices  for 
combining different analytical methods in support of decision 
18  STROETMANN, K.A. JONES, T. DOBREV, A. and STROETMANN, V.N. “eHealth is Worth it - 
The economic benefits  of implemented eHealth solutions at ten European sites”, Office for Official 
Publications  of  the  European  Communities,  Luxembourg,  2006  (56  pp.  -  ISBN  92-79-02762-X), 
available on www.ehealth-impact.org
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making,  especially  in  areas  where  societal  interest  is 
considerable like the healthgrid area, are becoming louder19.
6.2.2.2.Policy Development
The  question  is  simply  one  of  making  industry  and 
government organisations aware of the possibilities.
Making  someone  aware  of  a  possibility  is  nowadays  not 
sufficient,  yet  it  is  a  good  start.  Indeed,  industry  and 
government  organisations  should  be  made  aware  of  the 
potential that healthgrid has. The next step will be to convince 
decision  makers  that  it  is  worthwhile  to  invest  (not  only 
financial resources, also time, effort, influence, etc.) in realising 
this potential. One argument can be build around the challenge 
to provide the best possible health service to as many people as 
possible,  given the budget  constraints.  As the EU Council  of 
Ministers agrees, “a primary ethical challenge is to balance the 
needs  of  individual  patients  with  the  financial  resources 
available to treat the whole population”20.
healthgrids are one of the options to address this challenge. It has 
to be compared to alternative options, so that an optimal choice 
of tools for addressing the challenge is made. Such an analysis 
must be one of the actions on the roadmap towards healthgrid 
deployment.  Once  the  role  of  healthgrids is  established,  policy 
makers have to intervene, in that they change private incentives 
for  uptake  of  the  grid  technology  and  services  in  health 
provision where necessary.
19  MENACHEMI,  N.  et.  al.,  "Hospital  Information  Technology  and  Positive  Financial 
Performance:  A  different  approach  to  ROI”,  Journal  of  Healthcare  Management,  51:1, 
January/February 2006
20  “Council Conclusions on Common values and principles in European Union Health Systems”, 
Document (2006/C 146/01), Official Journal of the European Union on 22 June 2006, pp. 1 - 5
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6.2.2.3.Cross-Border  and  Cross-Institutional  Resource 
Allocation and Sharing, IPR and Patenting
It doesn't even have to cost a fortune since they will just be 
sharing their collaborator's resources." 
If  data  transfer  is  covered  by  existing  purposes  (flat  rate 
internet  access)  and  access  to  the  service  is  exchanged  for 
access  to  computer  power  (no  payment  for  computer)  then 
there  is  no expenditure incurred for  use of  the grid.  This  is 
consistent with results from the eHealth IMPACT study, which 
show that technical costs are often a relatively small part of a 
successful  eHealth  investment.  What  are often neglected are 
the change management and other organisational costs, which 
can constitute between 30% and 50% of the total investment 
cost21.  If  healthgrids are to be deployed successfully on a large 
scale,  the  organisational  component,  including  changes  in 
research, clinical, and working practices should receive a lot of 
attention.
It doesn't even have to cost a fortune since they will just be  
sharing their collaborator's resources." 
Assuming that the cost allocation issue is solved, for example in 
the way suggested above, there is still the question of sharing 
the  outcomes.  This  is  particularly  relevant  to  the  research 
applications,  in  the  illustrative  story  this  is  the  research 
conducted by the OXCCG. The Intellectual Property Rights and 
the  patenting  processes  have  to  be  solved  on  a  legal  basis. 
However,  the  behavioural  aspect  is  no  less  important.  The 
balance  between  competition  and  collaboration  is  difficult  to 
21  Results from “eHealth IMPACT – Study on the economic impact of eHealth”, Reports available 
on www.ehealth-impact.org
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get right. On the one hand, the healthgrid philosophy is based 
on collaboration and positive results are only possible following 
that  approach.  On  the  other  hand,  the  collaborating 
organisations are often in competition. For example, hospitals 
compete  for  patients  paying  higher  rates,  status,  and 
recognition.  Thus,  a  hospital  may  be  reluctant  to  provide  its 
facilities  if  they  are  likely  to  lead  to  success  of  its  direct 
competitor in the same town.
This  is  not  an  unsolvable  issue,  yet  it  can  prove  a  narrow 
bottleneck if not addressed in due time.
6.2.2.4.Reliance  on an Automated System –  Acceptance 
and Trust Technology and New Working Practices
“The real beauty is that the complicated computing is hidden 
from the scientist. The researchers submit code though a 
portal interface. It puts all the data in the right place and 
pulls  it  back  when  you  need  to  do  things  with  it. It's 
making the day-to-day life of the scientist a lot easier. Scientists 
want to focus on the life science without having to think about 
how these big machines work."
In  an  ideal  world,  in  which  everything  works  the  way  it  is 
intended  to,  this  vision  of  the  separation  of  roles  is  indeed 
appealing.  In  the  real  world,  however,  the  statement  of  Dr. 
Hernandez  opens  the  discussion  on  two  critical  features  of 
using healthgrid services as described in the story. The first of 
them is confidence and trust  in  a highly  complex technology 
solution.  The second is  the need for  changes in the working 
practices of health professionals and researchers.
Submitting a set of data into the systems and receiving a result 
within a few seconds is a substantial improvement to a scenario 
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in which manual processing of the data takes days or weeks. 
The  implicit  assumption  is  that  the  result  is  of  the  desired 
quality in both cases. Even if technically this is the case, the 
challenge is to convince the users. Indeed, health professionals 
and  scientists  are  usually  not  particularly  interested  in  the 
technical  details  of  computing.  This  also  leads  to  an 
understandable  sceptical  attitude  towards  such  technology. 
When the manual process is carried out by the scientist, he or 
she is confident in the results because of the understanding of 
how these  have  been  derived.  Lack  of  knowledge  about  the 
computing  processes  in  a  grid  may  thus  lead  to  lack  of 
confidence and trust in the derived results. This is in particular 
the case when grid processing is used for the purposes of acute 
healthcare treatment, where wrong analysis can lead to serious 
harm.  Lack  of  confidence  is  likely  to  lead  to  reluctance  by 
professionals to take up healthgrid services.
This  reluctance  may  be  further  reinforced  by  the  fact  that 
uptake of such services requires, if it is to deliver the expected 
benefits,  changes  in  clinical  and  working  practices.  For 
instance, Dr. Hernandez has to consult the OXCCG first, instead 
of  reaching  to  the  phone  for  an  emergency  ambulance.  She 
must also be able to make her enquiry to the OXCCG quickly, as 
well as interpret the results in real time. Otherwise, the delay 
may be lethal for her patient in case he really is suffering a 
stroke. This issue has already proven critical in implementing 
various eHealth solutions22.  Appropriate change management, 
leadership, and training have to be provided in order to avoid 
resistance to change to become an inhibitor to the deployment 
of healthgrids.
A  further,  related  aspect  is  the  perspective  the  third  party 
payer, usually some form of health insurance organisation. The 
required  new  working  practices  are  unlikely  to  fit  the 
reimbursement  schemes  designed  for  the  old  ones.  For 
22  see STROETMANN, K.A. JONES, T. DOBREV, A. and STROETMANN, V.N. “eHealth is Worth it - 
The economic benefits  of implemented eHealth solutions at ten European sites”, Office for Official 
Publications  of  the  European  Communities,  Luxembourg,  2006  (56  pp.  -  ISBN  92-79-02762-X), 
available on www.ehealth-impact.org
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example,  if  Dr.  Hernandez  is  paid  according  to  set  clinical 
pathways, she will be able to get her efforts reimbursed in case 
she makes a quick examination of Mr.  Sanchez and calls  the 
ambulance. In case she uses the OXCCG service, she will only 
be  able  to  invoice  the  insurance  company  for  the  quick 
examination at the start, and then for further treatment after 
the diagnosis.  She will  have to cover the cost of making the 
diagnosis  with  support  from  OXCCG  herself.  Indeed,  the 
marginal cost of making an enquiry to OXCCG, i.e. the cost of 
one extra enquiry once the system is in place, is nearly zero. 
The real cost, including a share of the associated development 
and maintenance costs of OXCCG, the training required to use 
the system efficiently, etc, is higher and someone has to bear it. 
Thus,  if  third  party  payers  do  not  accept  that  changes  in 
working  practices  associated  with  the  uptake  of  healthgrids 
require changes in reimbursement schemes, such changes will 
be very difficult to achieve.
6.2.2.5.Decision-Making based on a healthgrid Processes
The results of this in silico modelling can be used directly  
in day-to-day clinical practice. On the basis of the results 
she  receives  from  her  colleagues  at  Oxford,  Dr. 
Hernandez is able to diagnose that Mr. Sanchez in fact has a 
minor  congenital  abnormality  and  is  not  at  risk  of  MI.  She 
informs him and treats him instead for the mild chest infection 
that  had caused  the  pain  with  which  Mr.  Sanchez  originally  
presented.  On  the  basis  of  data  received  from  academic 
colleagues she is able also to inform Mr. Sanchez fully about the 
benign congenital heart defect.
Using healthgrid to receive instantly results that enable faster 
accurate  decision-making  is  a  desirable  goal.  Making  the 
correct diagnosis in real time instead of treating according to a 
different, assumed diagnosis is certainly an improvement in the 
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quality  of  healthcare23.  In  addition,  as  in  the  case  of  Mr. 
Sanchez, it can lead to considerable cost savings. 
The issue of relying on technology for decision-making in the 
health  sector  is  not  restricted  to,  yet  highly  relevant  for 
healthgrids.  At  the  heart  of  the  problem  lies  the  question  of 
accountability. When everything is the way it is expected to be, 
the  merits  of  the  above  scenario  cannot  be  reasonably 
questioned. The difficulty arises when things go wrong. Who is 
accountable for a wrong diagnosis? Is it  the doctor,  who has 
trusted technology more that she should have? Or is the doctor 
blame free, as long as she has followed the correct procedures? 
This problem should be addressed from a society point of view 
and regulated from a legal perspective. Otherwise, the created 
uncertainly will lead to strong resistance on behalf of those who 
are to use healthgrid services.
23  see for example, JACOBS, R. SMITH, P.C. and A. STREET, “Measuring Efficiency in Health 
Care”, Cambridge University Press, 2006
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7. CONCLUSIONS
The discussion above highlighted the important ethical,  legal 
and socio-economic issues that have to be addressed on the way 
towards  deployment  of  healthgrids.  The  analysis  is  preliminary, 
based  on  an  invented,  illustrative  story  and  will  be  further 
developed  on  the  basis  detailed  analyses  of  two  running 
healthgrid  solutions.  Nevertheless,  there  are  already  certain 
recommendations  that  can  be  made.  These  can  be  seen  as 
specific activities that will become part of the comprehensive 
roadmap  for  addressing  legal,  ethical,  social,  and  economic 
aspects of deploying healthgrids across the European Union. 
Broadly, these recommendations can be summarised as follows:
In terms of legal and ethical issues:
• A  careful  analysis  of  the  full  impact  of  data  protection 
legislation on the potential for healthgrid development within 
the context of an ethical respect for privacy is needed;
• A stepwise  approach  to  developing  the  liability  framework 
distributing  legal  responsibility  appropriately  across  the 
healthgrid  users  while  providing  legal  certainty  for  all 
stakeholders, including patients, is required; and
• The balance between control over intellectual property rights 
and  the  protection  of  investments  and  the  interest  of  a 
widespread  and un-predefined  community  in  interacting  in 
the use of grid applications needs to be reconsidered.
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Economic aspects of the use of grids in the health sector, as for 
any  investment  in  the  healthcare  sector,  will  need  to  be 
rigorously explored to build a convincing case:
• An  analysis  of  the  extent  of  desirability  of  healthgrids  is 
needed:  what  are  alternative  options  for  achieving the set 
goals?
• Also needed is  an analysis of stakeholder perspectives and 
incentives,  especially  as  regards  financial  implications  of 
healthgrid uptake.
• It  is  likely  that  interventions  aimed  at  adjusting  private 
incentives will be necessary. 
• Similarly, an adjustment of reimbursement schemes will likely 
need to follow to allow for sustainable uptake of new services 
that change clinical and working practices.
Finally, in order for the uptake and deployment of healthgrids to 
make a significant impact  on the delivery of  health services, 
social and behavioural issues must be addressed:
• Support and control the level of accurateness of results from 
using healthgrid processing;
• Ensure user confidence, based in particular on the above;
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• Facilitate  change  by  supporting  training  and  further 
education related to using healthgrids; and
• Facilitate  change  in  working  practices  by  minimising 
uncertainty and reducing risk for users.
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8. ANNEX I: DATA PROTECTION, CONFIDENTIALITY 
AND SECURITY ISSUES
Implementing a healthgrid generally implies the processing of a 
patient’s personal health data.
In Europe, such data are protected at EU level by different legal 
sources and at  national level  by diverse national legislations. 
But  although  personal  data  are  the  object  of  numerous 
European legislations,  the problem of the protection of these 
personal data (medical or not), still raises several questions that 
would be of importance in the implementation of healthgrids on 
the territory of the European Union, such as data processing, 
access  rights  for  data  subjects,  free  flows  of  personal  data 
within  the  Member  States  of  the  European  Union  or  data 
protection national legislations harmonization (see below Part I 
“Processing of Medical Data”).
It is also true that as the confidentiality and the protection of 
patients’  health  personal  data  are  governed  by  diverse 
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European  rules,  as  well  as  by  the  requirements  of  ePrivacy 
legislation  regarding  communications  infrastructure,  in 
practice,  the  confidentiality  requirements  make  healthgrids 
systems  security  critical  (see  below  Part  II  “Network 
Compliance with Confidentiality and Security Requirements”).
It is not so much the patient’s health data processing that is 
aimed here, but the question of the healthgrid in itself. Indeed, 
when a telematic network is set up, it already presents, among 
other risks, risks for the patient’s rights and the liberties. These 
particular risks  are very often spent  under silence or  simply 
ignored24. 
8.1. PART I: PROCESSING OF MEDICAL DATA
The key principles relevant to the processing of personal data 
were first established by the Council of Europe25, and further 
developed in Directive 95/46/CE of the European Union26.
The  latter  is  the  major  source  of  legislation27,  even  if  some 
Recommendations  made  by  the  Council  of  Europe  are  of 
importance for  the healthcare sector and for the use of  grid 
technology in that sector, since they are focusing on the field of 
medical data and scientific research28.
 
The purpose of the Directive is to allow the free flow of personal 
data  between the Member  States  of  the  European Union,  in 
24  On this question and on the definition of particular risks see HERVEG, J., “La gestion des 
risques spécifiques aux traitements des données médicales en droit européen”, to be published.
25  Convention No. 108 of the Council of Europe for the Protection of Individuals with regard to 
Automatic Processing of Personal Data adopted on 28 January 1981; Recommendation No. R (97) 18 of 
Committee of Ministers to Member States concerning the protection of personal data collected and 
processed for statistical purposes, adopted on 30 September 1997.
26  Directive 95/46/CE of the European Parliament and of the Council of 24 October 1995 on the 
protection of individuals with regard to the processing of personal data and free movement of such 
data, OJ L 281, of 23 November 1995, 31­50.
27  This is the reason why this text is analysed in particular. Further details of other documents 
governing medical data processing will be available in relation with the analysis of case scenarios. 
28  For an overview of all texts governing data processing, see Annex IV to document D4.2. See 
also GEMSS – Grid-enabled Medical Simulation Services and European Law – Final Report on all the  
legal issues related to running GRID medical services, 1-117.
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order to facilitate the establishment and the functioning of the 
internal market. 
The  second  objective  of  the  Directive  is  to  protect  the 
fundamental  rights  and  freedoms  of  natural  persons  and  in 
particular their right to privacy with respect to the processing 
of their personal data. 
The  protection  granted  by  the  Directive  does,  however,  go 
further than the protection of the natural person’s intimacy, i.e. 
generally  speaking,  the  protection  of  each  natural  person’s 
private life.  It  applies more particularly to any sensitive data 
relating  to  natural  persons  such  as  data  concerning  health, 
including mental health.  
As stated by senior researcher Jean Herveg at the healthgrid 
Conference 2006, in Valencia, “to be effective and coherent (the 
Directive had) to be built on the analysis of the risks capable to 
affect the fundamental rights and freedoms of the data subject.  
(Indeed)  it is only possible to determine the conditions under 
which personal  data  can  be  processed in  full  respect  of  the 
fundamental rights and freedoms of data subjects when these 
risks are identified” 29.
Prior to introducing the relevant provisions of the Directive that 
will impact the implementation of the grid technology for the 
29  HERVEG, J., “The Ban on Processing Medical Data in European Law: Consent and Alternative 
Solutions to Legitimate Processing of Medical Data in Healthgrid”, in Challenges and Opportunities of 
healthgrids, proceedings of Healthgrid 2006, HERNANDEZ, V. and others, Amsterdam, IOS Press, 108.
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biomedical sciences and in the healthcare sector (Part I C), we 
will begin by defining some key concepts (Part I A) useful in the 
application of data protection principles, outlining the scope of 
the Directive and presenting its principles relevant for medical 
data processing (Part I B).
The analysis will then come back on the specific cases of the 
transfer of  personal  data  between the Member  States  of  the 
European Union (Part I D) and of the transfer of such data to 
third countries located outside the European Union (Part I E).
Finally,  some  specific  rules  applicable  to  the  processing  of 
medical  and  genetic  data  not  contained  in  the  European 
Directive will briefly be presented (Part I F).
8.1.1.Part I: A: Key Concepts30
8.1.1.1.Personal data
According to Article 2(a) of the Directive,  the term ‘personal 
data’  relates  to  “any  information relating to  an  identified  or 
identifiable  natural  person  (‘data  subject’);  an  identifiable 
person is one who can be identified, directly or indirectly,  in 
particular by reference to an identification number or to one or 
more  factors  specific  to  his  physical,  physiological,  mental, 
economic, cultural or social identity”. 
According to this definition, personal data might concern any 
information regarding data subjects such as their names, their 
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e-mail addresses, their opinions, a sound or an image related to 
them, or their personal circumstances, whether these relate to 
their private, professional or public life.
Moreover, to be considered as personal data, data must relate 
to natural persons. Data strictly relating to companies, public 
bodies or other legal entities are not personal data. However, in 
some EU Member States  like Austria,  Luxembourg and Italy, 
data relating to companies are protected as personal data.
It  is  also  important  to  underline  that  personal  data  might 
concern persons who are alive,  but also dead persons at  the 
time of the processing. However, in some of the Member States 
as in Ireland, in Sweden or in the United Kingdom, personal 
data only concern living persons.
Finally  to  be  considered  as  personal  data,  data  must  allow 
direct or indirect identification of the data subject. 
Data allowing direct identification of the data subject are data 
that  can  be  easily  related  to  a  data  subject  and  reveal  his 
identity. This is the case with data such as names, addresses, 
dates of birth or even genetic data. These data when combined 
allow the identification of a data subject with a small margin of 
doubt. 
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Indirect  identification  requires  further  steps  to  make  a  link 
between a specific person and the data being processed. 
Therefore, the fact that data cannot permit to establish a direct 
link with a particular data subject does not necessarily imply 
that they do not constitute personal data. 
The possibility  to  identify  a  data  subject  through his  data  is 
assessed in abstracto31.  In other words, the mere existence of a 
possibility to establish a link between the data and a particular 
person is being sufficient to determine that personal data are 
involved. Therefore, coded, anonymous or pseudonymous data 
are  to  be  considered  as  personal  data  even  if  the  data 
controller32 does not have the code key to access the original 
data. 
However, in some Member States, such as the United Kingdom, 
Ireland, Austria or the Netherlands, the possibility to identify a 
data subject  through his  data  is  assessed  in  concreto,  which 
means that one should make his assessment taking into account 
the sole  information which is  or  which is  likely  to  be in  the 
possession of the controller and could help him to identify the 
data subject.
31  Indeed, Recital 26 of the Directive states “ […] to determine whether a person is identifiable, account 
should be taken of all means likely reasonably to be used either by the controller or by any other  
person to identify the said person; […]”.
32  See point 4 infra.
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8.1.1.2.Data subject
The data subject is generally defined as the person to whom the 
personal data relate.
8.1.1.3.Personal data processing33  
The concept of processing is very broad. It covers any operation 
or  set  of  operations  that  are  performed upon personal  data, 
whether or not by automatic means. 
In this frame, data processing is considered to be the collection, 
recording,  organisation,  storage,  adaptation  or  alteration, 
retrieval,  consultation,  use,  disclosure  by  transmission, 
dissemination  or  otherwise  making  available,  alignment  or 
combination, blocking, erasure or destruction of personal data. 
The  data  protection  legislation  covers  both  automated 
processing  and  non-automated  processing.  However,  non-
automated processing operations need to form part of a filing 
system or to be intended to form part of a filing system to be 
covered by the data protection legislation, i.e.  “any structured 
set of personal data which are accessible according to specific 
criteria, whether centralized, decentralized or dispersed on a 
functional or geographical basis” 34. 
33  Directive 95/46/CE, art. 2(b).
34  Directive 95/46/CE, art. 2(c).
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According to the Working Party on the Protection of Individuals 
with  regard  to  the  Processing  of  Personal  data  (also  called 
‘Article  29  Working  Group’),  the  concept  of  processing  also 
includes the operations performed on Internet by software and 
hardware, such as the uses of cookies, the data subjects being 
unaware of these operations35. 
8.1.1.4.Controller and processor
According to Article 2(d) of the Directive, the controller is the 
natural or legal person (a company) who alone, or jointly with 
others,  determines  the  purposes  and  the  means  of  the 
processing of personal data.  In every case,  it  is important to 
identify the data controller since he is the one liable for the 
legality  of  the  processing.  He  also  has  to  fulfil  obligations 
towards his national data protection authority and towards the 
data subjects.
On the other hand, according to article 2(e) of the Directive, the 
processor  is  the  natural  or  legal  person,  public  authority, 
agency  or  any  other  body  who  processes  personal  data  on 
behalf of the controller. 
This  will  typically  be  a  specialized  third-party  company 
entrusted by the controller to conduct the technical aspects of 
35  Recommendation  1/99  on  Invisible  and  Automatic  Processing  of  Personal  data  on  the  Internet 
performed by Software and Hardware adopted by the Working Party 16 on 23 February 1999.
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the  processing,  such  as  the  sorting  or  the  combination  of 
personal data. 
The employee of the controller in charge of the security and of 
the management of the computer system is not to be considered 
as a processor.
 
8.1.2.Part I: B: Scope and Principles of the Directive
8.1.2.1.Scope of the Directive
According to the European Directive as well as to Convention 
No.  108  of  the  Council  of  Europe  mentioned  above,  data 
protection principles apply to public and to private sectors. 
As explained here above, the Directive 95/46/CE applies to the 
processing  of  personal  data  wholly  or  partly  realised  by 
automatic  means,  and  to  the  processing  realised  by  non 
automatic means when the personal data processed form part 
of  a  filing  system  or  are  intended  to  form  part  of  a  filing 
system36.  
8.1.2.2.Relevant principles for medical data processing of 
the Directive
One  of  the  main  principles  of  the  Directive  relies  on  the 
conviction  that  the  risk  of  infringement  of  a  data  subject’s 
rights  and  freedoms  does  not  depend  on  the  information 
contained in his data. This risk depends on the purpose of the 
processing of these personal data. In other words, the potential 
or actual danger for the data subject’s fundamental rights and 
freedoms  has  to  be  assessed  regarding  the  purpose  of  the 
processing of personal data. The purpose refers to the general 
aim and framework of use of the personal data.  
The  principle  is  slightly  -though  not  entirely-  different  for 
special  categories  of  data  such  as  sensitive  data  or  medical 
36  Directive 95/46/CE, art. 3.
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data. Indeed, it is commonly admitted that the sole content of 
these  data  already  exposes  the  data  subject  to  the  risk  of 
infringement of his fundamental rights and freedoms, whatever 
the purpose of the data processing could be.
Therefore sensitive data require a special protection taking into 
account their content and the purpose of their processing. 
For this reason, and as stated in the Recital 33 of the Directive, 
“data  which  are  capable  by  their  nature  of  infringing 
fundamental  freedoms  or  privacy  should  normally  not  be 
processed […]”.
The  Directive  thus  banishes  the  processing  of  sensitive  or 
medical  data,  in  order  to  ensure  the  respect  of  the  data 
subject’s  fundamental  rights  and  freedoms  regarding  the 
processing of his medical data. 
However, the principle of the ban on the processing of sensitive 
and medical data is not absolute, as the full text of Recital 33 of 
the  Directive  states  that  “data  which  are  capable  by  their 
nature of  infringing fundamental  freedoms or  privacy  should 
normally  not  be  processed  unless  the  data  subject  gives  his 
explicit consent […]”.
The data subject’s explicit and valid consent37 thus constitutes 
the very first source of the legitimacy of the processing of his 
medical data even if, at the same time, it is the weakest base to 
legitimate  the  processing  of  medical  data  due  to  the  strict 
conditions  for  its  validity  and  to  the  possibility  for  the  data 
subject to revoke his consent to the processing of his medical 
data at any time and without justification (as will be explained 
below) 38. 
37  Directive 95/46/CE, art 8, 2(a).
38  As stated by senior researcher Jean Herveg, this empowerment of the data subject could surprise. One 
could indeed have doubts regarding the data subject’s capacity to consent, in a reasonable way, to the 
processing of his or her medical data, at a time when he or she is the weakest person in his or her 
relation to the health practitioner or at  least the demanding party in the processing of  his or her 
medical data. See HERVEG, J., “The Ban on Processing Medical Data in European Law: Consent and 
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Nevertheless  the  Directive  grants  permission  to  process 
medical data in six other hypotheses. 
Article 8, 2 of the Directive prescribes that:
“Paragraph 1  (i.e. the ban on the processing of medical data) 
shall not apply where:
[…]
(b) processing is necessary for the purposes of carrying out the 
obligations and specific rights of the controller in the field of 
employment law in so far as it  is authorized by national law 
providing for adequate safeguards; or
(c) processing is necessary to protect the vital interests of the 
data  subject  or  of  another  person  when  the  data  subject  is  
physically or legally incapable of giving his consent; or
(d)  processing  is  carried  out  in  the  course  of  its  legitimate 
activities  with  appropriate  guarantees  by  a  foundation, 
association  or  any  other  non-profit-seeking  body  with  a 
political,  philosophical,  religious  or  trade-union  aim  and  on 
condition that the processing relates solely to the members of 
the  body  or  to  persons  who  have  regular  contact  with  it  in  
connection with its purposes and that the data are not disclosed 
to a third party without the consent of the data subjects; or
(e) the processing relates to data which are manifestly made 
public by the data subject or is necessary for the establishment,  
exercise or defence of legal claims”.
The processing of  medical  data  is  equally  permitted when it 
“[…]  is  required  for  the  purposes  of  preventive  medicine, 
medical  diagnosis,  the  provision  of  care  or  treatment  or  the 
management of health-care services, and when those data are 
processed by a health professional subject to the obligation of 
professional  secrecy or by another person also subject to an 
equivalent obligation of secrecy” 39. 
Alternative Solutions to Legitimate Processing of Medical Data in Healthgrid”, op.cit.
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Finally,  the  European  Directive  offers  the  opportunity  to  the 
Member  States  to  add  exemptions  to  those  listed  above,  for 
reasons of substantial public interest.  These exemptions should 
be subject to suitable safeguards. For instance, under Article 8, 
4 of the Directive,  national exemptions might be adopted for 
scientific research or for social security reasons.
In the cases listed in Article 8, paragraphs 2, 3 and 4 of the 
Directive, the legitimacy of the processing of medical  data is 
formally  presumed.  This  presumption  has  been  settled  down 
because the situations described in the hypotheses listed above 
justify  the  processing of  medical  data.  The legitimacy  of  the 
processing of medical data is formally presumed, but without 
prejudice of the other conditions ensuring the lawfulness of the 
data processing.
8.1.3.Part I: C: The Lawfulness of the Data Processing
As regards medical data processing under the exceptions listed 
in Article 8 of the Directive, the other conditions ensuring the 
lawfulness of the data processing still apply. 
Indeed, Article 8 of the Directive is part of Chapter II of the text 
named “General  rules on the lawfulness of  the processing of 
personal data”, which also contains other provisions concerning 
the lawfulness of the processing of personal data. 
In  other  words,  one  could  see  Chapter  II  of  the  European 
Directive as a big concentric circle. Article 8 of the Directive, 
39  Directive 95/46/CE, art. 8, 3. See also Recommendation No. R (97) 5 of the Committee of Ministers to 
Member States on the protection of medical data, adopted on 13 February 1997, which foresees the 
same thing as the article 8, 3 of the Directive.
FP6­2005­IST­027694 PUBLIC  71 / 249
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, J. 
Herveg, V. Stroetmann, 
K. Stroetmann, A. 
Dobrev, C. Van 
Doosselaere, P. Wilson 
 
which relates to the processing of special categories of data (for 
instance medical data subject to a higher level of protection), 
would then be a smaller concentric circle included in the first 
one. 
It is thus logical that all the conditions of the first concentric 
circle listed below apply to the smallest concentric circle.
A single exception in this reasoning: Article 8 of the Directive 
darkens Article 7. To be qualified as legitimate, the processing 
of medical data does not have to correspond to one of the social 
justifications laid down by the European Directive in its Article 
7. It just has to correspond to one of the seven hypotheses listed 
in Article 8 of the Directive mentioned here above.
8.1.3.1.Conditions regarding the quality of the personal 
data 
As  provided  for  in  Article  6  of  the  Directive,  when  a  data 
controller needs to process specific data, these data must meet 
a certain level of quality and thus have to comply with different 
principles.
8.1.3.1.1.Personal data must be processed fairly and lawfully40
40  Directive 95/46/CE, art. 6, 1(a).
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The controller may process personal data only if such 
processing  is  done  in  accordance  with  the  relevant 
legislation and complies with good practices.
To  be  lawful,  the  processing  must  comply  with  the  data 
protection legislations at European and national levels. It must 
also comply with other legal requirements (for instance, special 
legal  texts  relating  to  the  medical  sector,  such  as  texts  or 
recommendation dedicated to medical secrecy). 
To  be  fair,  the  processing  must  be  transparent  to  the  data 
subject. This means that the controller has to comply with his 
information  duty  (as  we  will  see  below)  and  to  respect 
principles of good practices that should be listed in Codes of 
conduct.
8.1.3.1.2.Personal data must be collected for specified, explicit 
and legitimate purposes and not further processed in a 
way  incompatible  with  those  purposes.  Further 
processing of data for historical, statistical or scientific 
purposes  shall  not  be  considered  as  incompatible 
provided  that  Member  States  provide  appropriate 
safeguards41 
In order to grant a certain quality to personal data collected, 
the data controller has to define precisely the purpose of the 
41  Directive 95/46/CE, art. 6, 1(b).
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processing he plans to do and to communicate it  to the data 
subject and to his national supervisory authority. 
Each purpose must be legitimate, meaning that the interest of 
processing  must  outweigh the data  subject’s  interests  in  not 
having his data processed. In this framework one has to under-
line that the Directive’s text provides hypotheses where the le-
gitimacy of the data processing is presumed. But even in those 
hypotheses, the legitimacy has to be assessed a posteriori and a 
balance of interests has to be established. 
For  example  the  data  processing  could  be  legitimate  if  it  is 
necessary for the purposes of the legitimate interests pursued 
by the controller or by the third party or parties to whom the 
data are disclosed, except when such interests are overridden 
by the interests for fundamental rights and freedoms of the data 
subject.
To rely on this justification, the data controller should at first 
identify  the  interests  being  pursued  by  the  processing.  He 
would  then  have  to  determine  whether  these  interests  are 
legitimate (they must at least not violate any legal provision). 
Finally he would have to verify that the data processing does 
not  impact  the  data  subject’s  rights  and  liberties  in  a 
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disproportionate  way.  The  data  subject’s  rights  and  liberties 
should indeed prevail over the data controller’s interests. 
In order to assess the existence of prevalence, the controller 
takes into account the data subject’s interest in not having his 
data processed and any potential damage or distress that could 
be caused to the data  subject  by the processing of  his  data. 
Moreover, when the purpose of the processing can be achieved 
by different schemas of processing, the controller should always 
prefer  the one lesser  damaging or  inconvenient  for  the data 
subject.
The data collected may only be used for the initial purpose of 
the processing and should not be re-used for an incompatible 
purpose. When the data controller intends a new processing of 
the  data,  the  purpose  of  this  new  processing  has  to  be 
compared with the initial one in order to assess whether there 
is  a  close  relationship  between  both.  A  new purpose  that  is 
clearly  different  from the  initial  one  is  to  be  considered  as 
incompatible with the first one. 
When assessing whether the new purpose is compatible with 
the initial purpose of the processing, the data controller shall 
have  regard  to  the  context,  the  general  philosophy  of  the 
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second processing, as well as to any other relevant criteria as 
whether or not the secondary processing will be conducted by a 
third  party  or  as  whether  the  applicable  law  authorizes  a 
second processing or not.
However,  a  presumption  of  compatibility  with  the  initial 
purpose  of  the  processing  applies  to  further  processing  for 
historical, statistical or scientific purposes. Those purposes are 
considered compatible with the purpose for which the data had 
originally  been  collected,  provided  that  the  data  controller 
respects  the  specific  safeguards  foreseen  by  each  Member 
State. Therefore, it would be possible for the data controller to 
re-use data if the purpose of a second processing is scientific or 
statistical despite that it totally differs from the initial purpose 
of the processing. In this framework, the data controller must 
rely on the applicable national legislation in order to determine 
the conditions and how to comply with them. 
8.1.3.1.3.Personal data must be adequate and relevant and may 
not be excessive.42
Personal data must furthermore be useful and relevant 
as regards the declared purpose of the processing. It is 
42  Directive 95/46/CE, art. 6, 1(c).
FP6­2005­IST­027694 PUBLIC  76 / 249
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, J. 
Herveg, V. Stroetmann, 
K. Stroetmann, A. 
Dobrev, C. Van 
Doosselaere, P. Wilson 
 
thus forbidden to collect or to make use of irrelevant 
data that are not pertinent or not necessary to achieve 
the  purpose  of  the  processing.  The  data  controller 
should therefore avoid the use of personal data when 
the purpose of the planned processing can be achieved 
without it. 
On the other hand,  the data collected may not be excessive. 
This means that collecting certain data should not create a dis-
proportionate risk of undermining data subject’s  interests.  In 
this framework, useful data that are thought not indispensable 
to achieve the purpose of a processing have to be considered as 
excessive.
8.1.3.1.4.Personal data must be accurate and, when necessary, 
kept up to date.43
Another important matter to ensure the quality of the 
data is the accuracy of the processed data. To keep the 
data  accurate  and  when  necessary  up  to  date  is  an 
obligation of the data controller. He thus has to take all 
reasonable measures to fulfil his duty. He must prevent 
43  Directive 95/46/CE, art. 6, 1(d).
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from  processing  erroneous,  incomplete  or  obsolete 
data.
Moreover, when he knows that the data collected and processed 
are not accurate, he must either erase or rectify them.
8.1.3.1.5.Personal data should be stored for a limited period of 
time.44
The quality of the data is ensured by a last obligation 
lying on the data controller. Indeed personal data must 
not be kept in a form that permits the identification of 
the data subject for longer than what is necessary for 
the purposes for which they were collected or for which 
they are further processed.
As  soon  as  the  purpose  of  the  processing  can  be  achieved 
without using personal data, there is no need to conserve such 
data  any  longer.  Therefore,  they  should  be  rendered 
anonymous45 or be destroyed.
The Directive authorises the Member States to allow the data 
storage for a longer period of time, provided that the long-term 
44  Directive 95/46/CE, art. 6, 1(e).
45  For a detail  analysis  on anonyms data  and how to render a data anonymous in compliance with 
Directive 95/46/CE, please consult the reports to be published in the framework of the ACGT Project.
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storage aims at using the data exclusively to carry out scientific 
research  or  statistics.  Most  Member  States  have  transposed 
this provision of the Directive and their legislations provide for 
a special authorisation for long-term storage.
Recommendation  R  (97)  5  of  the  Committee  of  Ministers  to 
Member States of the Council of Europe on the protection of 
medical  data  adopted  on  13  February  1997,  also  authorises 
longer-term storage for interest of public health or in order to 
enable the controller to defend or exercise a legal claim. When 
a longer-term storage is rendered possible, security measures 
should be taken to ensure the correct conservation of the data46. 
8.1.3.2.Conditions  regarding  the  rights  of  the  data 
subject
Certain rights are granted to data subjects with regard to the 
processing of their data: a right of information, a right of access 
to their personal data, a right to request correction of the data 
and a right to object to the processing of the data under specific 
circumstances. The fact that these rights are recognised to data 
subjects  helps  to  protect  their  rights  of  privacy  and  their 
fundamental  liberties in more effective way. Furthermore, so, 
data subjects do not feel totally dispossessed of information that 
concerns them. When these conditions are not respected, the 
processing of personal data should be seen as unfair in respect 
of data subjects. The controller should therefore anticipate the 
likely exercising of these rights47. 
46  See Chapter II of this document.
47  The exercising of these rights specially requires the data controller to  take the technical measures 
that would be dealt with in the second Chapter (II) of this document.
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8.1.3.2.1.Right to be informed
Personal  data  can  either  be  obtained  directly  from the  data 
subject (which is called the ‘primary collection’) or be obtained 
from a distinct  alternative source of  data,  as a hospital  or  a 
doctor (which is called the ‘secondary collection’). 
The information to be given to the data subject is governed by 
Article  10  of  the  European  Directive  in  case  of  primary 
collection and by Article 11 in case of secondary collection.
8.1.3.2.1.1.Primary collection
Primary collection covers all situations where the personal data 
are  collected  directly  from the  data  subject,  including  those 
where the data subject ignores or is unaware of the fact that 
personal data are collected.
In this case, the controller or his representative (if any) must 
provide  the  data  subject  specific  information  relating  to  the 
processing. In order to protect his rights, the data subject must 
indeed learn about the existence of a processing operation on 
his data48. 
The  controller  will  thus  have  to  provide  at  least  his  identity 
(name,  address,  denomination  or  trade  name,  etc.)  and  his 
representative’s name (if any) 49.  
He will also have to provide a description of the purposes of the 
processing. These purposes have to be specified and explicit, 
which means that the precise description of the scientific or the 
statistical  project  is  to  be given.  The aim of  this  information 
obligation  is  to  indicate  what  the  data  will  be  used  for.  To 
inform the data subject that the data will be used for a scientific 
48  The information duty does thus not apply where the data subject has already been informed or when 
he already knows about the data processing.
49  Directive 95/46/CE, art. 10(a) and art. 11, 1(a).
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or for a statistical purpose is thus not enough. The data subject 
must  have  an  accurate  idea  of  what  the  research  or  the 
statistics planned by the data controller will be about.
The controller has to provide the data subject with additional 
information. When it is necessary to guarantee the fairness of 
the  processing,  this  additional  information  would  be  for 
example information about the categories of data concerned by 
the  processing,  about  the  recipients  or  the  categories  of 
recipients of the data, about the existence of a data subject’s 
right  of  access  to  his  data  or  about  the  existence  of  a  data 
subject’s right to rectify his data.
The  processing  of  sensitive  data  or  medical  data  normally 
requires the provision of further information. For instance, in 
case of genetic analysis,  the data subject should be informed 
about the objectives of the analysis and about the possibility of 
unexpected findings50.  
Finally  as  what  regards  the  timing  of  the  provision  of  the 
information, it should be given to the data subject at the same 
time when the data are collected, at the latest. However, when 
50  See Recommendation No. R (97) 5 of the Committee of Ministers to Member States on the protection 
of medical data adopted on 13 February 1997.
FP6­2005­IST­027694 PUBLIC  81 / 249
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, J. 
Herveg, V. Stroetmann, 
K. Stroetmann, A. 
Dobrev, C. Van 
Doosselaere, P. Wilson 
 
medical  data  are  collected  for  medical  emergencies,  data 
necessary for the medical treatment may be collected at first. 
In case of genetic analysis, the information should be given to 
the data subject before the genetic analysis is carried out.
8.1.3.2.1.2.Secondary collection
When personal data have not been obtained directly from the 
data subject, the controller should, before considering the way 
of processing these personal data or the right time to inform the 
data subject, assess whether they comply with the requirements 
for re-use of data51. 
The controller has to inform data subjects about any secondary 
collection at the latest at the time of recording, or if disclosure 
to a third party is anticipated, no later than the time when the 
data are first disclosed.
The duty of information does not apply where in particular for 
processing  for  statistical  purposes  or  for  the  purposes  of 
historical  or  scientific  research,  the  provision  of  such 
51  See paragraph 2.2. supra.
FP6­2005­IST­027694 PUBLIC  82 / 249
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, J. 
Herveg, V. Stroetmann, 
K. Stroetmann, A. 
Dobrev, C. Van 
Doosselaere, P. Wilson 
 
information  proves  to  be  impossible  or  would  involve  a 
disproportionate effort or if recording or disclosure is expressly 
laid down by law. Disproportionate effort may result when it is 
impossible to reach or contact data subjects (for example when 
the  controller  cannot  easily  obtain  their  addresses)  or  when 
contacting all data subjects can only be done at great expense, 
which  is  disproportionate  in  comparison  with  the  risk  of 
infringing their rights.
8.1.3.2.2.Right to access the data 52
All data subjects have the right to request specific information 
about  their  own  personal  data  that  are  processed  by  the 
controller.  Moreover,  where medical  data are processed, data 
subjects  may  ask  a  healthcare  professional  to  exercise  their 
access right. 
Upon  request,  the  controller  will  have  to  provide  the  data 
subjects  with  information  such  as  whether  or  not  he  his 
52  Directive 95/46/CE, art. 12(a).
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processing data relating to them. He will also have to inform 
them about  the  purpose  of  the processing,  the  categories  of 
data and the data being processed, the recipients or categories 
of recipients to whom the data are disclosed and the source of 
the data.
The Directive allows Member States to exempt the controller 
from  respecting  the  data  subject’s  access  right  where  the 
purpose of the processing is scientific research, or when data 
are kept in personal form for a period which does not exceed 
the period necessary to create statistics. 
The Directive, however, subjects the granting of that exemption 
to the condition that there is clearly no risk of breach of the 
data subject’s privacy. Moreover, data may not be used in order 
to  take  measures  or  decisions  regarding  any  particular 
individual.
8.1.3.2.3.Right to rectify the data
Under the Directive, a data subject has the right to ask for data 
to be corrected, erased or blocked where their processing does 
not  comply  with  the  provisions  of  the  Directive53.   This  is 
particularly  the  case  where  personal  data  are  incomplete  or 
inaccurate.
This  right  means  that  the  controller  must  correct,  erase  or 
block the data as required by the data subject, in a reasonable 
period.
Blocked  data  cannot  further  be  processed,  used,  or 
communicated without the data subject’s consent.
In  addition,  if  the  controller  has  disclosed  the  data  to  third 
parties, he has to notify them about any correction, erasure or 
blocking carried out. This notification of correction, erasure or 
53  Directive 95/46/CE, art. 12(b).
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blocking of data does not have to be performed if it proves to be 
impossible or involves a disproportionate effort54. 
The Directive allows Member States to exempt the controller 
from  the  obligation  to  respect  the  data  subject’s  right  of 
correction  in  case  of  processing  for  purposes  of  scientific 
research, or when data are kept in personal form for a period 
which  does  not  exceed  the  period  necessary  for  the  sole 
purpose of creating statistics55. 
8.1.3.2.4.Right to object to the processing
The last right granted to the data subject is the right to object 
to  the  processing  of  his  data.  When  there  is  a  legitimate 
objection to the data processing, the controller may no longer 
process the concerned data or communicate them to recipients.
According  to  the  Recommendation  No.  R  (83)  10  of  the 
Committee of Ministers to Member States on the protection of 
personal  data  used  for  scientific  research  and  statistics, 
adopted on 23 September 1983, where processing is conducted 
54  Directive 95/46/CE, art. 12 (c).
55  Directive 95/46/CE, art.  13, 2.
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for  scientific  or  statistical  reasons,  the  data  subject  may 
withdraw his collaboration. It this hypothesis, the data subject 
is entitled to ask the erasure of the data collected from him.
8.1.3.3.Duties of the controller56 
The controller has the obligation to ensure the security of the 
personal data processed, meaning that he must ensure that the 
data collected and stored are not lost, altered or accidentally 
destroyed.
These  duties  of  the  data  controllers  will  be  analysed  in  the 
second Chapter  of  this  Part  of  the  document  devoted  to  the 
network components of the grid technology.
8.1.4.Part  I:  D:  Transfer  of  Personal  Data  between 
Member States: the Impact of National Legislations 
The  transfer  of  personal  data  between  two  or  several 
controllers established on the territory of one Member States or 
56  Directive 95/46/CE, Section VIII ‘Confidentiality and Security of processing’.
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on  the  territories  of  several  Member  States  involves  on  one 
hand  a  problem of  communication  of  personal  data  to  third 
parties and on the other hand a problem of transfer of personal 
data.
8.1.4.1.Communication of personal data to third parties
As  regards  the  transfer  of  personal  data  between  different 
controllers established on the territory of one Member State or 
on the territories of different Member States, the first problem 
to be solved lies in the general  principle according to which 
controllers  should  refrain  from communicating  or  publishing 
personal data or otherwise making them public when it is not 
necessary to achieve the purpose of the processing. 
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Indeed, the transfer or the disclosure of personal data to third 
parties is considered as a processing operation and, as such, it 
is subject to the processing legal requirements. 
In  this  framework,  as  explained  above,  the controller  should 
check whether or not the transfer or disclosure of personal data 
falls within the scope of the initial purpose of the processing or 
is  still  compatible  with  this  purpose,  in  order  to  determine 
whether or not he can transfer or disclose the personal  data 
concerned.
The only data that can be transferred without being subject to 
these specific requirements are anonymous data. 
Finally, it is important to underline that the transfer of medical 
data is subject to additional specific requirements. 
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Medical data should not be communicated unless the conditions 
listed hereunder are fulfilled:
• medical  data  to  be  communicated  are  relevant  for  the 
communication purpose;
• the  recipient  of  the  communication  is  subject  to 
confidentiality  rules  equivalent  to  those  incumbent  to 
healthcare  professionals,  and  the  communication  is  legally 
authorised and is  realised  for  public  health  reasons  or  for 
another important public interest, to prevent a real danger or 
suppress a specific criminal offence, to protect the rights and 
freedoms  of  others  or  of  the  data  subject  himself  or  of  a 
relative in genetic line, to safeguard the data subject’s vital 
interests or a third person’s ones, to fulfil specific contractual 
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obligations or finally to establish, exercise or defend a legal 
claim.
Medical  data can also be communicated if  the first condition 
here above is met (i.e. data to be communicated are relevant for 
the communication purpose) and if the data subject (or his legal 
representative (if any) or an authority) has given his consent to 
the communication.
Last but not least, medical data relevant for the communication 
purpose may be communicated if the concerned data subject (or 
his  legal  representative  (if  any)  or  an  authority)  has  not 
explicitly objected to any non-mandatory communication, if data 
have been collected in a freely chosen preventive, diagnostic or 
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therapeutic context, and if the purpose of the communication, in 
particular  the  provision  of  care  to  the  patient,  or  the 
management  of  a  medical  service  operating  in  the  patient’s 
interest,  is  not  incompatible  with  the  purpose  of  the  initial 
processing.
But the communication of medical data between EU Member 
States also raises a problem of data transfer between different 
countries,  as the data protection national legislations are not 
fully harmonized.
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8.1.4.2.Transfer  of  personal  data  between  EU  Member 
States 
Under Article 32, 1, first paragraph of the European Directive, 
“Member States shall bring into force the laws, regulations and 
administrative  provisions  necessary  to  comply  with  this 
Directive […]”.
FP6­2005­IST­027694 PUBLIC  92 / 249
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, J. 
Herveg, V. Stroetmann, 
K. Stroetmann, A. 
Dobrev, C. Van 
Doosselaere, P. Wilson 
 
National legislations of the different EU Member States should 
be  harmonised  by  now,  and  the  transfers  of  personal  data 
between these Member States should not create any problem. 
For instance, a data controller established on the territory of 
one Member State should not fear by transferring the data he 
processed to another controller established in another Member 
State, that these data would not be correctly protected as the 
second Member State does not provide for the same level of 
protection of personal data as the first one.
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This would be the case if all Member States had transposed the 
Directive in the same way. 
But differences are already to be found in the member States’ 
legislations as  regards the definitions of  key  concepts of  the 
Directive such as ‘personal data’, ‘processing’ or ‘controller’.
Moreover,  the  Directive  itself  allows  the  Member  States  to 
“adopt  legislative  measures  to  restrict  the  scope  of  the 
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obligations and rights provided for in Articles 6 (1), 10, 11 (1),  






There  might  thus  be  differences  in  the  level  of  protection 
granted to personal data between the EU Member States, which 
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might be a problem for the implementation of the healthgrid 
technology on the whole territory of the European Union. 
However,  it  is  important  to  note  that  even  if  there  are 
differences in the levels of protection of personal data between 
the Member States, these differences are of minor importance, 
as the implementation of the Directive already ensures a high 
level of protection for personal data. These differences in the 
levels  of  protection  of  personal  data  between  the  Member 
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States  cannot  even  constitute  barriers  to  data  transfers  as 
Article 1, paragraph 2 of the Directive prescribes:
“Member States shall neither restrict nor prohibit the free flow 
of personal data between Member States for reasons connected 
with  the  protection  afforded  under  paragraph  1  (i.e.  the 
protection of data subjects’ fundamental rights and freedoms)”.
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This  is  not  always  the  case  as  what  regards  the  transfer  of 
personal  data  towards  other  countries  located  outside  the 
European Union and the European Economic Area (EEA).
8.1.5.Part I: E: Transfer of Personal Data to Non-EU (and 
Non-EEA) Countries 
The transfer of personal data outside the European Economic 
Area is governed by specific conditions57that need to be met in 
addition to the requirements for the communication of personal 
data to third parties analysed in point D, 1., here above.
The controller should refrain from transferring personal data to 
a recipient located in non-EEA countries, if the country involved 
does not ensure an adequate level of protection. 
Some countries, such as Argentina, Isle of Man, Guernsey and 
Switzerland,  have  been  recognised  by  the  European 
Commission as ensuring an adequate level of protection. This 
means that the European Commission has decided that these 
countries have a level of protection of personal data in some 
way equivalent to the one available in the Member States of the 
European Union.
The transfer of data to companies located on the territory of the 
United  States,  which  adhered  to  the  US  Department  of 
Commerce’s Safe Harbour Privacy Principles, is also allowed. 
57 Directive 95/46/CE, articles 25 and 26. The Council and the European Parliament have given the Com-
mission the power to decide, on the basis of Article 26 (4) of Directive 95/46/EC that certain standard 
contractual clauses offer sufficient safeguards as required by Article 26 (2), that is, they provide ad-
equate safeguards with respect to the protection of the privacy and fundamental rights and freedoms of 
individuals and as regards the exercise of the corresponding rights.
The effect of such a decision is that by incorporating the standard contractual clauses into a contract, 
personal data can flow from a data controller established in any of the Member States of the EU and in 
the three EEA member countries (Norway, Liechtenstein and Iceland) to a data controller established in a 
country not ensuring an adequate level of data protection. Moreover  on the 15 June 2001, the Commis-
sion adopted Decision 2001/497/EC on standard contractual clauses for the transfer of personal data to 
third countries. Recently, i.e. on 27 December 2006, the Commission adopted Decision C(2004)5271 
amending Decision 2001/497/EC as regards the introduction of an alternative set of standard contractual 
clauses for the transfer of personal data to third countries, O.J., L 385/74, 29 December 2004.
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The  European  Commission  moreover  allows  the  transfer  of 
personal data to recipients located on the territory of Canada, 
provided  that  these  recipients  are  subject  to  the  Canadian 
Personal Information Protection and Electronic Documents Act 
(also called the ‘PIPED Act’).  However, the PIPED Act mainly 
addresses  organisations  that  are  regulated  at  a  federal  level 
(federal works, undertakings or businesses) and not non-profit 
organisations.
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Regarding  the  other  countries,  it  is  up  to  the  controller  to 
assess whether or not they offer an adequate level of protection 
of personal data.
The controller can find all the same a loophole in the Directive. 
Indeed  the  Directive  provides  some  exemptions  to  the 
prohibition of transfer of personal data to countries not offering 
an adequate level of protection of personal data. 
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The most relevant exemptions contained in most of the national 
laws  with  respect  to  processing  for  research  and  statistical 
purposes are the following:
(a)the data subject has given his consent unambiguously to 
the proposed transfer; or
(b)the  transfer  is  necessary  for  the  performance  of  a 
contract between the data subject and the controller or 
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the implementation of pre-contractual measures taken in 
response to the data subject's request; or
(c) the  transfer  is  necessary  for  the  conclusion  or 
performance of a contract concluded in the interest of the 
data subject between the controller and a third party; or
(d)the transfer is necessary or legally required on important 
public interest grounds, or for the establishment, exercise 
or defence of legal claims; or
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(e) the  transfer  is  necessary  in  order  to  protect  the  vital 
interests of the data subject; or
(f) the transfer is made from a register which according to 
laws or regulations is intended to provide information to 
the public and which is open to consultation either by the 
public in general or by any person who can demonstrate 
legitimate interest, to the extent that the conditions laid 
down in law for consultation are fulfilled in the particular 
case58. 
Moreover,  the  Directive  states  that  Member  States  may 
authorise a transfer or a set of transfers of personal data to a 
third  country  that  does  not  ensure  an  adequate  level  of 
protection  of  personal  data,  where  the  controller  adduces 
adequate  safeguards  as  what  regards  the  protection  of  the 
privacy, fundamental rights and freedoms of individuals and the 
exercise  of  the  corresponding  rights.  Such  safeguards  may 
result, in particular, from appropriate contractual clauses59.  
The European Commission decided that  an adequate  level  of 
protection  of  personal  data  could,  in  particular,  be  achieved 
through a contract between the sender and the recipient of the 
personal  data.  In  this  frame,  the  European  Commission 
proposes standard contractual clauses that ensure an adequate 
level of protection of transferred personal data.
The European Directive does not set specific conditions for the 
transfer of medical data to non-EU (and non EEA) countries, but 
Recommendation  R  (97)  5  of  the  Committee  of  Ministers  to 
Member States on the protection of medical data, adopted on 
13 February 1997, does so. It establishes additional rules for 
the transfer of medical data to a country that does not have an 
equivalent  level  of  protection  of  medical  data  as  the  one 
granted on the territory of the European Union.
58  Directive 95/46/CE, art. 26, 1(a) to (f).
59  Directive 95/46/CE, art. 26, 2.
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Under these circumstances, the person responsible for the data 
transfer should indicate to the recipient the initial purpose of 
the processing as well as the persons or the bodies to whom the 
data may be communicated.
On the other hand, the recipient should honour the purpose he 
accepted and should not communicate the data to other persons 
or other bodies than those indicated by the person responsible 
for the data transfer.
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8.1.6.Part  I:  F:  Additional  Specific  Rules  for  the 
Processing of Medical and Genetic Data
The European Directive does not contain all the rules relating 
to the processing of medical or genetic data.
Some specific rules relating to the processing of medical data 
have  been  proposed  by  the  Council  of  Europe  within 
Recommendation  R  (97)  5  of  the  Committee  of  Ministers  to 
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Member States on the protection of medical data, adopted on 
13 February 1997.
As  provided  by  this  Recommendation,  only  healthcare 
professionals  or  individuals  or  bodies  working  on  behalf  of 
those healthcare professionals should carry out the processing 
of medical data. Those individuals or bodies should be subject 
to  confidentiality  rules  equivalent  to  those  incumbent  on 
healthcare professionals60. 
60  This requirement is equivalent to the one contained in Article 8, 3 of the European Directive which 
provides that  ‘Paragraph 1 shall not apply where processing of data is required for the purposes of  
preventive medicine,  medical  diagnosis,  the provision  of  care or treatment or the management of  
health-care services, where those data are processed by a health professional subject under national  
law or rules established by national competent bodies to the obligation of professional secrecy or by  
another person also subject to an equivalent obligation of secrecy”.
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Moreover medical data must normally be obtained directly from 
the data  subject,  but  it  is  possible  to  obtain  such data  from 
other sources of information when some conditions are met (as 
provided for in the Directive).
Finally,  medical  data  should  not  be  communicated  to  third 
parties unless some conditions are met.
As regards the processing of genetic data, the Recommendation 
No. R (97) 5 establishes specific rules. In the framework of the 
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Recommendation,  genetic  data  collected  and  processed  for 
preventive treatment, diagnosis or treatment of the data subject 
or  for  scientific  research,  should  only  be  used  for  those 
purposes or in order to allow the data subject to take a free and 
informed  decision  on  the  opportunity  of  such  treatments  or 
researches.
On the other hand, the collection and processing of genetic data 
should, in principle be permitted only for health reasons and in 
particular  it  should  be  authorised  to  avoid  that  any  serious 
prejudice  would  be  caused  to  the health  of  data  subjects  or 
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third parties. The collection and processing of genetic data may 
though  be  authorised  in  order  to  predict  illness  in  cases  of 
overriding interests. In this case, both operations will be subject 
to appropriate safeguards defined by the applicable legislation.
It is also important to underline that other specific rules exist 
for the processing of other person identifying data,  when the 
purpose of the processing is scientific or statistical.
Recommendation R (83) 10 of the Committee of Ministers to 
Member  States  on  the  protection  of  personal  data  used  for 
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scientific  research  and  statistics,  adopted  on  23  September 
1983, proposes different principles for the processing of these 
data for research or statistics purposes.
When it is possible, the researches should be undertaken with 
anonymous data. However, if using anonymous data renders the 
research  impossible,  personal  data  may  be  used.  Under  the 
circumstances  that  health  data  are  use  to  achieve  scientific 
researches,  specific  conditions listed by the Recommendation 
No. R (97) 5 must be met.
Indeed, personal data may not be used for another purpose than 
the one of the research itself, nor be used to take a decision or 
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to undertake any action directly affecting the data subject, nor 
be used for another research project substantially different in 
its nature or in its objects from the initial one, except if the data 
subject gave his consent.
The personal data may not be published unless the data subject 
has consented to the publication and under the circumstances 
that the national law allows it. 
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8.2. PART II: NETWORK COMPLIANCE WITH 
CONFIDENTIALITY AND SECURITY REQUIREMENTS
As said in the Part I of the analysis, personal data processing 
has consequences,  for example  as regards the data subjects’ 
rights. When their data are processed, the law recognises them 
certain  rights.  In  this  framework,  the  data  controller  should 
anticipate the likely exercising of these rights by adapting his 
system.
The networks hosting data processing are thus to be adapted to 
it  and  to  be  adapted  to  all  the  consequences  in  terms  of 
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confidentiality  and  security  (Part  II  B)  and  in  terms  of 
notification duty (Part II C).
On  the  other  hand,  as  stated  by  Professor  Yves  Poullet,  the 
creation  of  new telematic  infrastructures  raises  the  question 
about the person (natural or legal person) responsible for the 
infrastructure61.  The  answer  to  this  question  should  not  be 
neglected, as the “network controller” would be responsible for 
the conception and the quality of the network.
61  HERVEG, J. and POULLET, Y.,  Which major legal concerns in future e-Health?,  e-Health and Health 
Policies, Synergies for better health in a Europe of Regions, Plenary session: e-health and new social 
dilemmas, to be published. JH comments that this paper has been published: details needed.
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8.2.1.Part II: A: Confidentiality and Security Issues
Data processing confidentiality and security requirements are 
mainly regulated by Directive 95/46/CE. The 8th section of the 
European Directive is dedicated to these issues.
As what regards the confidentiality necessarily linked with the 
data processing, Article 16 of the Directive provides that  “any 
person acting under the authority of the controller or of the  
processor including the processor himself,  who has access to 
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personal  data  must  not  process  them except  on  instructions 
from he controller, unless he is required to do so by law”.
The controller must ensure the confidentiality of the personal 
data, meaning that unauthorised access to them or disclosure 
must be prevented.
On  the  other  hand,  Article  17  of  the  Directive  governs  the 
security of the processing.
According to Article 17 of the Directive, the controller has the 
obligation to ensure the security of the personal data processed, 
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meaning that he must ensure that the data are not lost, altered, 
or accidentally destroyed.
As  said  before,  the  controller  must  also  ensure  the 
confidentiality of the personal data processed.
In  order  to  achieve  those  two  purposes,  the  controller  must 
implement appropriate technical  and organisational  measures 
to  protect  personal  data  against,  for  instance,  accidental  or 
unlawful destruction or accidental loss, alteration, unauthorised 
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disclosure  or  access,  in  particular  where  the  processing 
involves the transmission of data over a network, and against all 
other  unlawful  forms  of  processing62.  In  other  words,  the 
controller has to construct his system to render it sufficiently 
secure for the processing of personal data. 
As well, he might have to adapt the organisational structure of 
his company to ensure the confidentiality and the security of the 
data processed63. 
This  means  that  the  protection  of  the  data  enclosed  in  the 
system has an impact on the system itself. The data controller 
62  Directive 95/46/CE, art. 17, 1, § 1.
63  An example of an organisational measure could be the appointment of a data protection officer in 
charge of the data protection issues. On the other hand, technical measures could include restricted 
access to the databases to authorized persons and the utilisation of software protecting the system 
against viruses or hacking.
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must  collaborate  with  the  network  controller  to  fulfil  the 
confidentiality  and  security  requirements.  The  infrastructure 
must be confidential to protect patients’ rights. It must also be 
secure and stable to prevent any damage to the data collected, 
processed and stored.
According to the law64,  the appropriate level  of  protection to 
ensure depends of the state of the art, the cost of the system 
implementation, the sensitisation and the staff training in data 
processing,  the risks  represented by the processing,  and the 
nature of the data to be protected (for instance sensitive data 
like health data require a higher level of protection).
Recommendation  R  (97)  5  of  the  Committee  of  Ministers  to 
Member States on the protection of medical data, adopted on 
13 February 1997,  gives some example of the measures that 
could  be  taken  when  medical  data  are  processed.  The  data 
controller  and  the  system  controller  could,  following  the 
examples given in the Recommendation, control the entrance to 
their  installations  (by  using  a  password),  to  prevent  any 
unauthorised person to have access to the data.
Moreover, both controllers should appoint a person responsible 
for  the  security  of  the  information  system  and  for  the  data 
protection.
It  can  also  happen  that  the  controller  will  not  be  the  one 
processing the data, but that he would appoint another person 
(named  the  ‘processor’)  to  process  the  data  on  his  behalf. 
Article  17,  2  of  the  European  Directive,  regulates  this 
hypothesis.
Under  these  circumstances,  the  data  controller  must  take 
reinforced  security  and  confidentiality  measures  because  the 
information he collected are transferred to another person who 
will  process  it.  He  should  then  ensure  that  the  processor 
64  Directive 95/46/CE, art. 17, 1, § 2.
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provides sufficient guarantees on technical security measures 
and on organisational measures governing the processing to be 
carried  out  and  on  the  fact  that  he  will  comply  with  those 
measures. 
Moreover in this case the European Directive requires the data 
processing  to  be  governed  by  a  contract  or  by  a  legal  act 
binding  the  processor  to  the  controller  and  stipulating  in 
particular that the processor shall only act on the instructions 
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of the controller and that he should be responsible for taking all 
appropriate technical and organizational measures.
In view of keeping proof, the parts of the contract or of the legal 
act binding the processor and relating to the data protection 
shall be in written form or in another equivalent form65. 
For  technicians,  it  may  seem  difficult  to  comply  with  the 
confidentiality and the security constraints, especially as they 
are  actors  non  subject  to  medical  deontology  or  medical 
65  Directive 95/46/CE,  art. 17, 4.
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secrecy. In a general way, the creation and the implementation 
of healthgrids in the healthcare sector in particular may be in 
conflict  with  traditional  rules  relative  to  medical  secrecy. 
However,  information society  technologies may provide many 
solutions to these problems66. 
8.2.2.Part II: B: Notification Duty
In  order  to  ensure  some  kind  of  publicity  and  transparency 
around  the  existence  and  scope  of  any  processing,  the 
controller is required, prior to carrying out the processing, to 
66  Directive 2002/58/EC provides, in its Articles 4, 5, 6 and 9, rules concerning the security and the 
confidentiality  of  electronic  communications  but  unfortunately  only  for  infrastructures open to the 
public and accessible to him.
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provide the relevant national supervisory authority with certain 
pieces of information regarding the processing he is planning to 
conduct.  The  information  recorded  will  then  normally  be 
accessible to data subjects or to third parties.
This does not really concern the network or the system with 
which the processing will  be undertaken,  but  it  requires the 
system  to  satisfy  to  the  confidentiality  and  security  legal 
requirements,  as  the  national  supervisory  authority  will  be 
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aware of its existence and will be able to check whether or not 
it satisfies to the legal requirements.
The notification will notably cover the identity of the controller, 
the purpose of the processing, the categories of data subjects, 
the recipients, and the transfers to third countries. 
However, the exact content of the notification has to be defined 
by the different national laws and further specified by National 
Data Protection Authorities.
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9. ANNEX II: LIABILITY ISSUES
As we saw in the Annex I, implementing a healthgrid generally 
implies the processing of patients’ personal health data, which 
implies risks for patients’ rights and liberties.
Implementing  a  healthgrid  and  using  it  in  a  hospital  for 
instance,  implies  other  risks  for  patients.  Indeed  in  case  of 
malfunctioning of  the system or  of  problem in  the supply  of 
services, patients could be harmed.
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The  issue  in  the  case  of  damages  caused  to  patients  by  a 
malfunctioning of the system or by a product or service part of 
the system, is that there are currently no specific guidelines or 
liability rules available to solve potential problems.
Originally,  the  medical  liability  issue  appeared  in  the 
relationship  between  a  patient  and  a  healthcare  practitioner 
(usually a doctor). Thus, when a patient was victim of medical 
negligence or of a medical error, the solution would be quite 
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simple:  he  would  take  legal  action  against  his  doctor  or 
prosecute him. 
Quickly,  a  new  actor  appeared  within  the  framework  of  the 
treatment of diseases and illnesses, in the event of error or of 
negligence of the healthcare practitioner, namely the insurance 
company of the healthcare practitioner. 
Determining  the  responsibilities  for  each  one  became  even 
more  difficult,  when  the  patient  was  taken  in  charge  by  a 
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medical team or by different healthcare practitioners members 
of a hospital service. Who should be regarded as liable in the 
event of problems? The doctor? All the members of the medical 
team in charge of the patient? The hospital? 
New questions arise as the complexity of the relations between 
patients and doctors increases: What is the responsibility of the 
doctor delivering a second opinion, in case of accident? What is 
the patient’s responsibility in the damage that was caused to 
him? What about the State’s liability, i.e. in the organisation and 
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the  monitoring  of  the  health  activities?  What  could  be  the 
responsibility  of  the  pharmaceutical  companies  in  issuing 
dangerous  medicinal  products  when  those  products  were 
prescribed by doctors?
Nowadays,  the  implementation  of  healthgrids  notably  in  the 
healthcare  sector  introduces  even  more  difficulties  in  the 
determination of responsibilities in case of damage cause to a 
patient.
Even if at first the medical liability has to be considered in the 
relationship  between  the  patient  and  the  healthcare 
practitioner,67 the  establishment  of  the  person  to  be  hold 
responsible  for  a  specific  damage  can be  problematic  taking 
into  account  the number  of  intermediaries  participating to  a 
healthgrid  and  the  complexity  of  such  a  system  involving 
different  actors  such  as  doctors,  specialists,  hospitals, 
pharmaceutical  companies,  data  controllers  and  processors, 
technicians, etc., often located in different countries.68
Although there are no specific liability rules applicable to products and to services 
that   are   supplied   by   the   healthgrid   systems  or   that   compose   them,   a   general 
principle exists that products and services provided to consumers must comply with 
certain level of quality.69 
67  The principle is that a patient victim of a medical negligence or error will at first bring proceedings 
against his doctor.  The generalist is thus the front line in case of medical damages caused to a patient.
68  As stated by senior researcher Jean HERVEG in the report Product Liability and Consumer Protection 
(to be published in the context of  the INFSO financed study “Legally  eHealth”),  in the healthcare 
practice, the patient is nowadays frequently aware of the different intermediaries in charge of his file. 
In case of damage, he could then logically bring proceedings against them rather than against his 
doctor.  Difficulties  could  then  occur  from  the  differences  in  the  way  their  responsibility  is  been 
engaged.  On  the  other  hand,  the  patient  is  more  and  more  in  charge  of  his  health,  without  the 
intervention  of  a  healthcare  practitioner.  Thus,  beyond the articulation  of  the different  healthcare 
practitioners’  liability,  there  are  situations  where  the  patient  is  no  more  taken  in  charge  by  a 
healthcare  practitioner.  Under  these  circumstances,  the  patient  stands  alone  against  the 
pharmaceutical companies or the medical devices companies which might be subject of different rules 
regulating their liability. It might thus be impossible for the patient to find an interlocutor and to obtain 
compensation for the damage caused to him. JH proposes to delete this note – need explanation.
69  This principle applies mutatis mutandis to business-to-business relations. See Chapter II: Liability as 
regards the system’s components of this document infra.
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At   first,   we   shall   thus   analyse   the   European   legislation   applicable   to   the 
information contained in the healthgrid systems or to the products and the services 
supplied by  these systems  (Part   I).  We shall approach  then  the useful   texts   to 
determine  the   responsibilities   of   the  different  actors  of   healthgrids,   as   for   the 
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9.1. LIABILITY AS REGARDS THE SYSTEM’S CONTENT
As stated in the first part of this document, healthgrids mainly contain patients’ 
medical data, such as personal data, insurance data, medical images, radiographies, 


















9.1.1.Part I: A: Liability as regards the Data 
As stated in the first part of this document, processing of personal data requires 
security   and   confidentiality   of   information   highways.   These   requirements 
70  When a healthgrid is use in the biomedical sciences, in the life science, in the medical research or in 
the drug discovery sectors, it contains wealth data, molecular biology data or medical images.
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71  Directive 95/46/EC, art. 16.
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In terms of security, this implies that the data controller in due cooperation with the 
network   controller   must   implement   appropriate   technical   and   organisational 
measures to protect personal data.
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example   prove   that   a   default   of   maintenance  of   the   system   by   the   network 
controller gave raise to the patient’s damage.
72  Directive 95/46/EC, art. 22.
73  Directive 95/46/EC, art. 23, § 2.
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9.1.2.Part I: B: Liability as regards Products
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However,   the  delivery  and  the  use of   these products may  induce  liabilities  of 
persons active  in  the healthcare  sector and  treating patients  through healthgrid 
systems, as healthcare practitioners, medical device producers,75  pharmaceutical 
companies,   hospitals,   etc.   They   may   also   induce   liabilities   of   actors   of   the 
biomedical sciences sector such as biomedical experts, or of the drug discovery 
sector.








74  This  is  already  the  case  at  a  London hospital  where  an  ePharmacy  has  been  set  up  through  a 
combination  of  ePrescribing,  eDispensing  using  a  robot  system,  eStockmanagement  and 
eProcurement, for outpatients and discharged patients.
75  As regards the liability of these persons, see Chapter II of this document.
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Texts   applicable   to   products   delivered   by   means   of   healthgrid   systems   are 
essentially Directive 2001/95 of the European Parliament and of the Council of 3 
December  2001  on  general  product  safety   (1.1.)   and  Directive  2001/83 of   the 
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76  Directive 2001/95 of the European Parliament and of the Council of 3 December 2001 on general 
product safety, O.J. L11, of 15 January 2002, 4-17.
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In  the  framework  of  Directive  2001/95,  the  term  ‘product’ 
means any product which is intended for consumers or likely, 
under  reasonably  foreseeable  conditions,  to  be  used  by 
consumers even if not intended for them, and which is supplied 
77  For a definition of all key concepts of the Directive and for a detailed analysis of the Directive’s text 
see VEREECKEN, I. and HERVEG, J., Product Liability and Consumer Protection, Part II: Analysis of the 
relevant legal texts, (to be published in the context of the INFSO financed study “Legally eHealth”).
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or  made  available,  whether  for  consideration  or  not,  in  the 
course  of  a  commercial  activity,  and  whether  new,  used  or 
reconditioned.
Therefore, products initially reserved for professional use that 
are subsequently made available to consumers are also covered 
by the Directive’s definition of the term product.
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On the other hand, a safe product is any product which, under 
normal and reasonably foreseeable conditions of use including 
duration,  does  not  present  any  risk  or  only  minimum  risks 
compatible with the product’s use, considered to be acceptable 
and consistent  with  a  high  level  of  protection of  consumers’ 
safety and health.
A dangerous product does thus not meet the definition of ‘safe 
product’.
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The  provision  of  services  is  excluded  from the  scope  of  the 
Directive,  but  the products supplied to consumers within the 
framework  of  the  supply  of  a  service  are  included  in  the 
Directive’s scope.
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9.1.2.1.1.3.General safety requirement 
The basic principle included in the Directive is that producers 
are obliged to place only safe products on the market.
Some criteria are thus proposed in the Directive’s text in order 
to assess if a product complies with the safety requirement. For 
instance, a product is deemed safe only once it conforms to the 
specific EU provisions governing products’ safety.
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Products   producers  and  distributors  also   have   their   obligations,   as   mentioned 
above.78
9.1.2.1.1.4.Duty of the EU Member States
Member  States  have  to  established  or  designated  national 
authorities in order to monitor the product safety and to take 
appropriate measures as regards risky products. 
78  For an overview of producers and distributor’s obligations, see Legally e-Health: Product Liability and 
Consumer Protection, opcit.
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Every  national  authority  must  ensure  that  producers  and 
distributors comply with their duties and are entitled to ensure 
the product safety by organising checks on safety properties, by 
imposing producers to warn adequately on the possible risks, by 
prohibiting  dangerous  products  to  be  marketed,  by  alerting 
consumers on the risks of a product already marketed and by 
organising recalls and destruction of products when necessary. 
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9.1.2.1.1.5.Information system 
Directive 2001/95 aims to create an efficient information system 
in order to help EU Member States,  national authorities and 
consumers to react quickly in order to avoid or to reduce any 
harm caused to persons’ health and safety.
The producers and distributors who discover that a product is 
dangerous  must  notify  the  information  to  the  competent 
national authority and collaborate with it. 
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The  European  Commission  is  in  charge  of  reinforcing 
cooperation between the different national  authorities and of 
promoting exchange of information and expertise by setting up 
a  European  product  safety  network  between  these  national 
authorities. 
When  a  national  authority  adopts  a  measure  linked  with  a 
serious risk that may have an effect beyond its territory, it shall 
inform the European Commission via the system for the rapid 
FP6­2005­IST­027694 PUBLIC  148 / 249
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, J. 
Herveg, V. Stroetmann, 
K. Stroetmann, A. 
Dobrev, C. Van 
Doosselaere, P. Wilson 
 
exchange of information between the Member States and the 
European Commission (also called the ‘Rapex’ system) of the 
identity of the product, the risks, the measures taken and the 
information  on  the  distribution,  including  the  destination 
countries. This information will be communicated to the other 
Member States. . 
The European Commission can also approve rapid measures at 
Community level  when it  becomes aware of a serious risk in 
various  Member  States.  After  consulting  the  Member  States 
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and a scientific committee when scientific questions arise, the 
Commission may adopt a decision (like the recall of the product, 
for instance) to be implemented by the Member States within 
less than 20 days. 
9.1.2.1.2.Directive 2001/83 on medicinal products79
79  Directive  2001/83  of  the  European  Parliament  and  of  the  Council  of  6  November  2001  on  the 
Community code relating to medicinal products for human use,  O.J. L311,  of 28 November 2001, 67-
128.
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In the Directive’s framework a medicinal product is defined as 
any  substance  or  combination  of  substances  presented  for 
treating or preventing disease in human beings or which may 
80  For a definition of all key concepts of the Directive and for a detailed analysis of the Directive’s text 
see Legally e-Health: Product Liability and Consumer Protection, opcit.
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be  administered  to  human  beings  with  a  view  to  making  a 
medical  diagnosis  or  to  restoring,  correcting  or  modifying 
physiological functions. 
On the other hand,  a medicinal prescription is any medicinal 
prescription issued by a qualified professional person.
9.1.2.1.2.2.Directive’s scope
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Directive  2001/83  applies  to  industrially  produced  medicinal 
products  for  human  use  and  intended  to  be  placed  on  the 
market in the Member States.
9.1.2.1.2.3.Principle of authorisation 
In the frame of the Directive, no medicinal product may be placed on the market, 
distributed, manufactured of imported unless a marketing authorisation has been 
issued by  the competent  national authorities of  the  relevant Member States. A 
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information (such as  the name of  the product,  route of administration, adverse 
reactions, expiry date, etc.). 
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Under   certain   conditions,   the   patient   can   obtain   the   repair   of   the   undergone 
damage.81
9.1.2.2.Repairing a damage
When a defective product causes damages, rules contained in 
Council  Directive  85/374  concerning  liability  for  defective 
products will apply.82 
This  Directive  aims  at  ensuring  a  high  level  of  consumer 
protection against  damage caused to health or property by a 
defective product. It also aims to reduce the disparities between 
national liability laws which distort competition and restrict the 
free movement of goods. Finally,  it  implements a system that 
extends the producer’s liability (called the ‘strict  liability’)  in 
order to protect consumers. 
Indeed, Directive 85/374 establishes the principle of objective 
liability or liability without fault of the  producer, importer and 
under  some conditions the supplier, in case of damage caused 
by a defective product. The producer, importer or supplier, will 
be liable and must pay compensation for  damages caused to 
persons or properties but only for that resulting from a defect. 
The burden of proof on the injured person is lighter. The person 
does  not  have  to  prove  that  the  producer  was  at  fault  or 
negligent; he just needs to prove the damage, the defect and 
the causal relationship between defect and damage. 
When the producer, importer or supplier, is considered as liable, 
he must pay compensation for the damage caused to the person 
or to his properties, but only for that resulting from a defect.
81  For more details about the advertising of medicinal products, see Legally e-Health: Product Liability 
and Consumer Protection, opcit.
82  Council  Directive  85/374  of  25  July  1985  on  the  approximation  of  the  laws,  regulations  and 
administrative provisions of the Member States concerning liability for defective products, O.J. L210, of 
7 August 1985, 29-33.
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Though, in order to strike a reasonable balance between the 
interest of the consumer and the need to encourage innovation 
and  technological  development,  the  Directive  contains  some 
rules protecting the producer.  Indeed, under some particular 
circumstances,  the  producer may be  exonerated  from  all 
liability. Moreover, the injured person has a limitation period of 
three years to seek compensation. This period starts from the 
day on which the plaintiff became aware, or should reasonably 
have become aware of the damage, the defect and the identity 
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of  the  producer.  After  that,  no  further  compensation  will  be 
possible.  In  any  case  the  producer’s  liability  is  limited  to  a 
period of ten years from the date on which the producer put the 
product into circulation. This time limit is intended to preserve 







what was foreseen  in  the contract, one will  often refer  to  the relevant national 












83  Directive 1999/44 of the European Parliament and of the Council of 25 May 1999 on certain aspects of 
the sale of consumer goods and associated guarantee, O.J. L171, of 7 July 1999, 12-16.
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In  the  framework  of  Directive  1999/44,  the  definition  of  the 
consumer is  the same as the one of  Directive 1997/7 on the 
protection of consumers in respect of distance contracts.85
The consumer has thus to be seen as any natural person who, in 
the contracts covered by the Directive, is acting for purposes 
which are not related to his trade, business or profession.
On the other hand, consumer goods covered by the Directive 
are any tangible movable item (except goods sold by authority 
of law, water and gas where they are not put up for sale in a 
limited volume or set quantity, and electricity). 
Moreover, the seller is any natural or legal person who, under a 
contract,  sells  consumer  goods  in  the  course  of  his  trade, 
business  or  profession,  when the  producer  is  defined  as  the 
manufacturer  of  consumer  goods,  the  importer  of  consumer 
84  For a definition of all key concepts of the Directive and for a detailed analysis of the Directive’s text 
see Legally e-Health: Product Liability and Consumer Protection, opcit.
85  Directive 1997/7 on the protection of consumers in respect of distance contracts, O.J. L144, of 4 June 
1997, 19-27.
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goods  into  the  territory  of  the  Community  or  any  person 
purporting to be a producer by placing his name, trademark or 










9.1.2.3.2.Principle of conformity with the contract 
The  seller  has  to  deliver  to  consumers  goods  that  are  in 
conformity with the contract of sale.
Consumer  goods  are  presumed to  be  in  conformity  with  the 
contract if they: 
(a)comply with the description given by the seller and 
possess the qualities of the goods which the seller 
has held out to the consumer as a sample or model; 
(b)are fit for the purposes for which goods of the same 
type are normally used;
(c) are  fit  for  any  particular  purpose  for  which  the 
consumer requires them and which he or she made 
known to the seller at the time of conclusion of the 
contract and which the seller has accepted; 
(d)show the quality and performance which are normal 
in goods of the same type and which the consumer 
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can  reasonably  expect,  given  the  nature  of  the 
goods  and  taking  into  account  any  public 
statements  on  the  specific  characteristics  of  the 
goods made about them by the seller, the producer 
or  his  or  her  representative,  particularly  in 
advertising or on labelling. 
9.1.2.3.3.Liability of the seller in case of lack of conformity 
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The  principle  exists  that  the  seller  shall  be  liable  to  the 
consumer for any lack of conformity that exists at the time the 
goods were delivered.
Any  lack  of  conformity,  which  becomes  apparent  within  six 
months  of  delivery  of  the  goods  shall  be  presumed  to  have 
existed at the time of delivery unless proved otherwise or if this 
presumption is incompatible with the nature of the goods or the 
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The seller shall not be bound by public statements, if he:
• shows that he was not, and could not reasonably have been, 
aware of the statement in question, 
• shows that,  by  the  time of  conclusion of  the  contract,  the 
statement had been corrected, or
• shows that the decision to buy the consumer goods could not 
have been influenced by the statement.
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Equally   simulations   and modelling   for   therapy  planning  and  computer­assisted 
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shall   thus be governed by ordinary rules of  law applicable  in  the different EU 
Member States, which might not be satisfactory.
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86  For more information on this subject, see IAKOVIDIS, I., eHealth & Patient safety, Myths, Visions and 
Realities, eHealth Congress, Brussels 19 October 2006.
87  IOM, 2000 ; Starfield, 2000.
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What about the responsibility problematic in such circumstances (Part II)?
9.2. PART II: LIABILITY AS REGARDS THE SYSTEM’S 
COMPONENTS
As   stated   by   several   researchers   at   the   healthgrid   Conference   2006,   hold   in 
Valencia in June 2006, the emergence of grid technology opens new perspectives to 








It   is   thus   composed of  products  such  as  Electronic Health  Records   (hereafter 
‘EHR’) containing patients’ information, computers, networks, powerful computing 





88  BRETON, V., BLANQUER, I, HERNANDEZ, V., LEGRE, Y. and SOLOMIDES, T., "Proposing a roadmap 
for  healthgrids",  in  Challenges  and  Opportunities  of  healthgrids,  HERNANDEZ,  V.  and  others, 
Amsterdam, IOS Press, 2006, p. 319.
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In  case of  failing of  the healthgrid  system,  there will  be  thus  two systems of 
liability, as the failing will be due to a product (A) or to a service (B).
9.2.1.Part II: A: Liability as regards Products
The concept of the products components of healthgrids is a difficult one, because 
in  practice  it   includes a   lot  of   different   things.  These products will  be   either 
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software packages or hardware devices with embedded software (radio frequency 
identification   location   trackers   for   locating   people   and   objects   or   remotely 
controlled medical devices). 
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electrical   and   electronic   equipment92  (also   called   the   ‘RoHS’   Directive)   will 
provide the purchaser with certainty about certain aspects of a product’s quality (2).
9.2.1.1.Directive 1993/42 on medical devices
When a product that will be placed on the market is considered 
as  a  medical  device,  specific  additional  rules  regarding  the 
safety of those particular products apply. 
The Council Directive 93/42 concerning medical devices93 aims 
notably to safeguards patients’ and users’ health and safety by 
89  For details on this point, see Chapter I, point B, of this document.
90  Directive 2001/95 of the European Parliament and of the Council of 3 December 2001 on general 
product safety, opcit.
91  Directive 1999/44 of the European Parliament and of the Council of 25 May 1999 on certain aspects of 
the sale of consumer goods and associated guarantee, opcit.
92  Directive 2002/95 of the European Parliament and of the Council of 27 January 2003 on the restriction 
of  the use of  certain hazardous substances  in electrical  and electronic  equipment,  O.J.  L37,  of  13 
February 2003, 19-23.  
93  Council Directive 93/42 of 14 June 1993 concerning medical devices, O.J. L169, of 12 July 1993, 1-43.
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harmonizing the conditions  for placing medical devices on the 
market and putting them into service. 
Among other conditions, medical devices must be designed and 
manufactured in such a way that their use do not compromise 
the safety and health of patients, users and other persons when 
properly  installed,  maintained  and  used  in  accordance  with 
their intended purpose.
The  manufacturer should  meet  some  essential  requirements 
and notably eliminate or reduce the risks as far as possible. 
Moreover EU Member States are involved in the protection of 
the  patients.  Indeed  when one  of  them remark  notes  that  a 
medical  device  conform  to  the  Directive’s  prescriptions 
compromises  the  health  and/or  safety  of  patients,  users  or, 
where  applicable,  other persons,  it  shall  take all  appropriate 
interim measures to  withdraw it from the market, prohibit or 




According  to  the  Directive’s  text,  a  ‘medical  device’  means 
“ […] any instrument, apparatus, appliance, material or other 
article,  whether  used  alone  or  in  combination,  including the 
software necessary for its proper application intended by the 
manufacturer to be used for human beings for the purpose of: 
• diagnosis, prevention, monitoring, treatment or alleviation of 
disease, 
• diagnosis,  monitoring,  treatment,  alleviation  of  or 
compensation for an injury or handicap, 
94  For a definition of all key concepts of the Directive and for a full comment on the Directive’s text see 
Legally e-Health: Product Liability and Consumer Protection, opcit.
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• investigation, replacement or modification of the anatomy or 
of a physiological process, 
• control of conception,
and which does not achieve its principal intended action in or 
on  the  human  body  by  pharmacological,  immunological  or 
metabolic means, but which may be assisted in its function by 
such means”.
The  accessories  which  are  not  medical  devices  as  such,  but 
which  are  specifically  intended  to  be  used  together  with  a 
device to enable it to be used as wanted by the manufacturer, 
shall be treated as medical devices.
Furthermore,  electronic  equipments  and  software  must  be 
regarded as enclosed within the definition of medical  device, 
when they are manufactured or promoted for medical purpose. 
Indeed, according to the Guidelines  relating to medical devices   
Directives95 available  on  the  website  of  DG  Enterprise,96 
software  related  to  the  functioning  of  medical  devices  are 
medical devices on their own if placed on the market separately 
from the related devices. When a piece of software assists in 
making the diagnosis (like image enhancing software created 
for diagnostic purposes), or if it is used a therapeutic tool, it 
must be considered as a medical device. This is not the case for 
software used for the administration of general patient data. 
Finally  when a  product  has  multiple  purposes  (such  as  PCs, 
printers, screens, etc.) it should only be considered as a medical 
device if it has a specific medical purpose (as underlined here 
above). 
95  These  guidelines  aim  at  promoting  a  common  approach  by  manufacturers  and  Notified  Bodies 
involved in the conformity assessment procedures according to the relevant annexes of the Directives, 
and by the Competent Authorities charged with safeguarding Public Health. Nevertheless, they are not 
legally  binding.  However,  due to the participation of  the aforementioned interested parties  and of 
experts from Competent Authorities, it is anticipated that they will  be followed within the Member 
States and, therefore, ensure uniform application of relevant Directive provisions.
96  For  details  and  references  see 
http://ec.europa.eu/enterprise/medical_devices/meddev/index.htm.
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As what regards the manufacturer, he is defined as the natural 
or legal person with responsibility for the design, manufacture, 
packaging and labeling of a device before it is placed on the 
market  under  his  own  name,  regardless  of  whether  these 
operations  are  carried  out  by  that  person  himself  or  on  his 
behalf by a third party. 
The manufacturer’s obligations set out in the Directive,  must 
also  be filled by  the natural  or  legal  person who assembles, 
packages, processes, fully refurbishes and/or labels one or more 
ready-made  products  and/or  assigns  to  them  their  intended 
purpose as a device. This subparagraph does not apply to the 
person who, while not being a manufacturer within the meaning 
of the first subparagraph, assembles or adapts devices already 
on  the  market  to  their  intended  purpose  for  an  individual 
patient.
9.2.1.1.1.1.General safety requirement 
In the Directive’s frame, manufacturers are obliged to place on 
the market or to put into service only medical devices that do 
not compromise the safety and health of patients, users and, 
where  applicable,  other  persons,  when  properly  installed, 
maintained  and  used  in  accordance  with  their  intended 
purpose.
The  manufacturer  must  design  and  manufacture  medical 
devices in such a way that some ‘essential requirements’ are 
met, such as to take into account the generally acknowledged 
state of the art  and to eliminate or reduce risks as much as 
possible (like the risks linked to the toxicity of certain materials 
and their incompatibility with biological tissues and cells, or the 
risks  of  contamination  for  persons  involved  in  the  transport, 
storage and use of medical devices)
Devices  that  are  in  accordance  with  the  national  provisions 
transposing the existing  European harmonised standards  will 
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be  presumed  by  EU  Member  States  as  compliant  with  the 
essential requirements laid downed by the Directive.
Devices other than those which are custom-made or intended 
for clinical investigation must bear a CE conformity mark when 
placed on the market.
FP6­2005­IST­027694 PUBLIC  179 / 249
B O T T L E N E C K S  & 
C H A L L E N G E S  A N D  R T D 
R E S P O N S E S  F O R  L E G A L , 
E T H I C A L ,  S O C I A L ,  A N D 
E C O N O M I C  A S P E C T S  O F 





Date: I. Andoulsi, J. 
Herveg, V. Stroetmann, 
K. Stroetmann, A. 
Dobrev, C. Van 
Doosselaere, P. Wilson 
 
Products  composing healthgrid  systems that  are electrical  or 





RoHS   Directive   relating   to    the   restriction   of   the   use   of   certain   hazardous    
substances in electrical and electronic equipment.    
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This   Directive   imposes   to   manufacturers   to   avoid   the   use   of  lead,   mercury, 
cadmium,   hexavalent   chromium,   polybrominated   biphenyls   (PBB)   or 
polybrominated diphenyl ethers (PBDE) in those equipments. 
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on  the   insertion   interdiction of   certain hazardous compounds  in   electrical   and 
electronic equipments.
Finally,  it  should be noted that national,  European and international bodies are 
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standards’   for   medical   digital   images.   Though   these   standards   are   not   legally 
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data   and   knowledge   management   services.   A   citizen   might   thus   be   seriously 
harmed or   even   die,   if   the   information   transmitted   to   the  general   practitioner 
treating him is not accurate or false, or if it is not supplied on time.
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In   the   same way  that   for   the   services  supplied  by   the   system,  for   those who 
compose it, there is not either a liability rules harmonisation. 
In case of problems with the services composing the healthgrid systems liability 
shall   thus be governed by ordinary rules of  law applicable  in  the different EU 
Member States.
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However, when Internet services are part  of a healthgrid, Directive 2000/31 on 
certain   legal   aspects   of   information   society   services,   in   particular   electronic 
commerce,   in   the   Internal   Market97  (also   called   the   ‘Directive   on   electronic 
commerce’) might apply. 





pharmacist   running a health   related website,   this  means  that  they will  have  to 











97  Directive 2000/31 of the European Parliament and of the Council  of 8 June 2000 on certain legal 
aspects of information society services, in particular electronic commerce, in the Internal Market, O.J. 
L178, of 17 July 2000, 1-16.
98  Communication from the Commission to the Council,  the European Parliament, the Economic and 
Social Committee and the Committee of Regions, “eEurope 2002: Quality Criteria for Health related 
Websites”, COM/2002/0667 final.
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and permit   to  threat  them when necessary.  Patients could  then stay home and 
introduce their health data on a website (even via browser, cell phone or PDA) were 
web­based personal health   records would be stored. To be  reliable  this   system 
would have to respect the quality criteria set by the European Commission as what 
regards for instance accessibility for the patients. Indeed putting a medical device 
in   the   hand   of   persons not   familiar   with   it  might   pose  problems   or   even   be 
dangerous. To be effective the system presented would have to be easy to use by 
patients.
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some  particular  rules  apply,  as  Directive 2001/83  authorises  the advertising of 





Council   of   11   May   2005   concerning   unfair   business­to­consumer   commercial 
practices  (also   called   the   ‘Unfair   Commercial   Practices   Directive’),99  any 
commercial   practices  (including   advertising)  directly   connected   with   the 
promotion, sale or supply of a  product  (including service) to consumers must be 
fair. This Directive explains when a practice should be considered as unfair. All 






Directive 2005/29/EC thus bans  unfair commercial practices  such as  misleading 
practices, failing to provide the consumer with the information needed or with false 
information,   and  aggressive   practices,   like   harassment,   coercion   or   undue 
99  Directive 2005/29 of the European Parliament and of the Council of 11 May 2005 concerning unfair 
business-to-consumer commercial practices in the internal market, O.J. L149, of 11 June 2005, 22-39.
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As mentioned above, Directive 2000/31 furthermore implements 
special rules of exoneration of liability.
These rules may minimize the risks  for  technical  partners  of 
eHealth  services  providers,  who  act  as  ‘intermediaries’.  For 
instance,  in  principle,  a  company that  provides  to  one of  its 
clients (an ePharmacy, for instance) a server space for web site 
hosting, will not be liable for the illegal sale of medical products 
or for the damage caused by wrong information delivered to 
patients.
The  Directive  establishes  a  special  exoneration  system  of 
liability  for  some  categories  of  Internet  intermediaries 
providing information society services called ‘Mere Conduit’ (1), 
‘Caching’ (2) and ‘Hosting’ (3) under specific circumstances. 
9.2.2.2.1.Mere Conduit 
The “Mere Conduit” is an information society service consisting 
of:
• the transmission in a communication network of information 
provided by a recipient of the service or
• the provision of access to a communication network.
When  providing  such  a  “Mere  Conduit”  service,  the  service 
provider is not liable for the information transmitted. 
Though to benefit from this exemption of liability, the provider 
has to comply with several cumulative conditions:
• the provider does not initiate the transmission; 
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• the provider does not select the receiver of the transmission; 
and
• the  provider  does  not  select  or  modify  the  information 
contained in the transmission.
The acts of transmission and of provision of access include the 
automatic,  intermediate  and  transient  storage  of  the 
information transmitted in so far as this takes place for the sole 
purpose of carrying out the transmission in the communication 
network, and provided that the information is not stored for a 
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period  longer  than  what  is  reasonably  needed  for  the 
transmission.
However, the liability exemption does not affect the possibility 
for  a  Court  or  an  Administrative  Authority  from  asking  the 
service  provider  that  he  prevents  infringements  or  that  he 
terminates it when they arise. 
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9.2.2.2.2.Caching
The “Caching” is  an information society service consisting of 
the  transmission  in  a  communication  network  of  information 
provided by a recipient of the service. 
When providing such “Caching” service, the service provider is 
not  liable  for  the  automatic,  intermediate  and  temporary 
storage of that information, performed for the sole purpose of 
making more efficient the information's onward transmission to 
other recipients of the service upon their request. 
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To  benefit  from this  liability  exemption,  the  provider  has  to 
comply with several cumulative conditions:
• the provider does not modify the information; 
• the  provider  complies  with  conditions  on  access  to  the 
information; 
• the provider complies with rules regarding the updating of 
the information, specified in a manner widely recognised and 
used by industry; 
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• the  provider  does  not  interfere  with  the  lawful  use  of 
technology, widely recognised and used by industry, to obtain 
data on the use of the information; and
• the provider acts expeditiously to remove or to disable access 
to  the  information  it  has  stored  upon  obtaining  actual 
knowledge  of  the  fact  that  the  information  at  the  initial 
source  of  the  transmission  has  been  removed  from  the 
network, or access to it has been disabled, or that a court or 
an  administrative  authority  has  ordered  such  removal  or 
disablement.
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As for ‘Mere Conduit’ services, the liability exemption does not 
affect the possibility for a Court or an Administrative Authority 
from asking the service provider that he prevents infringements 
or that he terminates it when they arise.
9.2.2.2.3.Hosting
The  “Hosting”  service  consists  of  the  storage  of  information 
provided by a recipient of the service. 
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When providing such “Hosting” service, the service provider is 
not liable for the information stored at the request of a recipient 
of the service. 
To benefit from this exemption, the provider has to comply with 
several cumulative conditions:
• the provider does not have actual knowledge of illegal activity 
or  information  and,  as  regards  claims  for  damages,  is  not 
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aware  of  facts  or  circumstances  from  which  the  illegal 
activity or information is apparent; or
• the provider, upon obtaining such knowledge or awareness, 
acts  expeditiously  to  remove  or  to  disable  access  to  the 
information.
The service provider may not benefit from this exemption when 
the recipient of the service is acting under his authority or his 
control.
This   liability   exemption   does   not   affect   the   possibility   for   a   Court   or   an 
Administrative   Authority   from   requiring   the   service   provider   to   prevent   an 
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infringement or to terminate it, when it occurs, nor does it affect the possibility of 
establishing   procedures   governing   the   removal   or   disabling   of   access   to 
information.
For  example  the  Internet  service  provider  that  gives  server 
space for  a company’s  or  an individual’s  website  will  not  be 
liable for the information stored, when he does not know about 
the illegality of the information or if he is aware of the illegality 
of the information stored and prevents access to it. 
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When  the  provider  has  a  control  on  the  information  -for 
instance when he is acting as an editor- he cannot benefit from 
the exoneration system provided for in the Directive. 
9.2.2.2.4.No general obligation to monitor information 
Finally,  it  is  important  to  underline  that  when providing  the 
three information services described above, providers can not 
be obliged to monitor the information which they transmit or 
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store,  nor  to  seek  actively  facts  or  circumstances  indicating 
illegal activity.
On the contrary, they may be obliged to promptly inform the 
competent  public  authorities  of  alleged  illegal  activities 
undertaken  or  of  information  provided  by  recipients  of  their 
services  or  to  communicate  to  the  competent  authorities,  at 
their  request,  information  enabling  the  identification  of 
recipients  of  their  services  with  whom  they  have  storage 
agreements.
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To determine the responsibility or the absence of responsibility 
for each of the actors of the network becomes easier, at least 
when the grid infrastructure is located on the Internet.
Criteria others than the use of Internet also allow to determine 
the responsibilities in case of damage caused by the healthgrid 
system.
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9.3. PART III: OTHER CRITERIA AS REGARDS LIABILITY
When products and services destined to patients or to end­users of the healthgrid or 
designed   to   be   part   of   the   system   are   supplied   in   certain   circumstances,  the 
responsibility of eHealth actors can be easier to determine.
9.3.1.Part III: A: Contracts 
Much eHealth business will necessarily involve the conclusion of contracts. These 
contracts  contain   the description of   the parties’  obligations and, often,  special 
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The delivery of eHealth products and the provision of eHealth services could also 





100  Directive 97/7 on the protection of consumers in respect of distance contracts,  O.J. L144,  of 4 June 
1997, 19-27.
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to   business­to­consumer   transactions   and   to   business­to­business   transactions, 
excepted when the professional parties are allowed to agree otherwise.
The   application   of   two   directives   have   for   consequence   that   healthcare 
professionals,   scientist,   researchers,   services  providers   and  other   actors   of   the 
healthgrid   will   have   a   duty   to   provide   consumers/patients/users   with   some 
information.
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From   his   part,   the   Directive   on   electronic   commerce   provides   for   a   list   of 
information  relative   to   the   formation of   contracts,  such   as   information on   the 
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Different   kinds  of   electronic   signatures   exist,   from  the  very   simple  ones  (the 
insertion of a scanned hand­written signature within an electronic document), to 
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Directive  1999/93 on electronic  signature  provides  the conditions  for   the  legal 
recognition of any electronic signatures. When the signature is based on a public 
key   cryptography   system   (advanced   electronic   signature),   it   benefits   a   more 
favourable  regime. But any  kind of  electronic   signature may enjoy some  legal 
effects. 
The main principle of   the  Directive   is   the  introduction of  a   legal  equivalence 
between the hand­written signature and the advanced electronic signature based on 
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the   hand­written   signature,   does   not   allow   the   judges   to   refuse  it.   The   legal 
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10.ANNEX III: INTELLECTUAL PROPERTY ISSUES
The healthgrid vision relies on setting up of grid infrastructures 
for medical research, healthcare and the life sciences.
This implies the availability of data organised in databases.
This also implies the availability of grid services, most notably 
for data and knowledge management.101 
A full functioning healthgrid will then be composed of a data 
grid, i.e. a distributed and optimised storage of large amounts 
101  These services  must  be  deployed on  infrastructures  involving  healthcare  centres  (e.g.  hospitals), 
medical  research  laboratories  and  public  health  administrations.  For  details  on  this  point  see, 
SOLOMONIDES,  T.,  Structuring  and  supporting  Healthgrids  Activities  and  Research  in  Europe 
(SHARE): towards a European Healthgrid, step on, e-Science 2006, Amsterdam, 4-7 December 2006.
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of accessible information and of a computing grid which implies 
the utilisation of numerous computers, computer programmes 
and  other  electrical  components.  The  final  part  of  a  full 
healthgrid would be a knowledge grid or in other words, the 
intelligent  use  of  a  data  grid  for  knowledge  creation.  This 
knowledge grid has not yet been deployed.
As we repeatedly mentioned in this document, a healthgrid is 
thus mainly composed of computer and computer programs and 
encompasses databases.
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With the implementation of healthgrids on the territory of the 
European Union,  the  protection of  databases  will  assume an 
increased  importance,  given  that  most  grid  services  will  be 
provided via electronic databases accessible online or offline or 
accessible  via  European-wide  networks.  Databases  should 
therefore be accorded an appropriate level of protection so as 
to  create  an  attractive  environment  for  investments  while 
safeguarding user’s interests (Part I).
On  the  other  hand,  the  deployment  of  Healthgrids  on  the 
territory of  the European Union will  mean that grid services 
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such  as  data  management  services,  and  products  such  as 
computer programs will be provided. 
However,  once  a  product  or  a  service  has  been  provided,  it 
becomes very difficult, without adequate protection to ensure 
that a literary or artistic work or other protected matter will not 
be copied, transformed or exploited without the knowledge or 
the right holders and contrary to their interests. This is even 
truer  when  products  or  services  are  provided  on  a  network 
vastly deployed.
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Moreover, as one knows the implementation of Healthgrids will 
require the development of new services. In this framework, the 
creative effort, which provides a basis for investment in these 
new services, will be worth undertaking only if works and other 
matter are adequately protected by copyright.
Finally owing to the very nature of grids, any wide variation in 
the level  of  protection of  works and other matter  may place 
obstacles  in  the way of  their  development.  Indeed,  grids  are 
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intended to be deployed on a large scale on the territory of the 
European Union. Thus, given the difficulty of verifying the use 
made of  a  work,  and the scope for  displacement  of  business 
which  this  opens  up,  there  is  a  need  for  more  far-reaching 
harmonisation  of  the  protection  provided  by  copyright  and 
related rights.
The  objectives  listed  above  were  mainly  realised  by  three 
directives  on copyright  and related  rights  (II).  As  mentioned 
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above, this legal framework was completed with the Directive 
on the legal protection of databases.
10.1.PART I: INTELLECTUAL PROPERTY RIGHTS AND 
DATABASES 
As  researchers  Laura  Vilches  Armesto  and  Philippe  Laurent 
write,  lawyers  usually  address  medical  data  from  a  privacy 
point of view. Nevertheless, they continue by saying:
“However  intellectual  property  is  increasingly  put  forward 
when  discussing  the  control,  the  use  or  the  transmission  of 
medical  data.  Even if  medical  data relates to patients and is 
moreover protected by very strict data protection and secrecy 
rules,  this  information  is  nonetheless  “created”,  sorted, 
structured,  explained  and,  more  generally,  processed  by 
professional  practitioners  and medical  administrations.  Given 
this  processing of  the  data  and drafting of  files  and reports 
concerning  health  condition  of  patients,  one  could  indeed 
assume  that  these  intellectual  investments  should  be  worth 
some legal protection”.102
This is not the case only for medical data. Some adequate legal 
protection is required for molecular data, cellular data, tissue 
data and even population data.
The Directive on the legal protection of databases, which was 
adopted in February 1996, could apply to databases constituted 
of  medical,  genetic  or  even  general  data,  as  regards  its 
definition of a database. The first part of this chapter will thus 
be dedicated to the presentation of that directive (A).
The second part of this chapter will then be dedicated to the 
conflicts existing between copyright and patients’ rights (B).
102  VILCHES  ARMESTO,  L  and  LAURENT,  P.  “Intellectual  property  on  medical  data  chimaeras  and 
actuality”, Acts of the 16th World Congress on Medical Law, Toulouse, 7-11 August 2006, p. 747-754.
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10.1.1.Part I: A: Directive 96/9 on the Legal Protection of 
Databases
The  purpose  of  the  European  legislators,  by  adopting  the 
Directive 96/9/EC of the European Parliament and the Council 
of 11 March 1996 on the legal protection of databases,103 was 
above  all  of  providing  harmonised  copyright  protection  to 
databases. 
The  Directive  also  sought  to  create  a  legal  framework  that 
would establish the ground rules for the protection of a wide 
variety of databases in the information age. It did so by giving a 
high level of copyright protection to “original” databases104 and 
a new form of “sui generis” protection to those databases which 
were not “original” in the sense of the author’s own intellectual 
creation  (those  databases  are  also  called  “non-original” 
databases).  In  other  words  the  directive  introduced  a  new 
specific sui generis right for the creators of databases, whether 
or not these have an intrinsically innovative nature.
10.1.1.1.Directive’s scope
The Directive defines a database as “a collection of independent 
works,  data  or  other  materials  arranged  in  a  systematic  or 
methodical  way  and  individually  accessible  by  electronic  or 
other means”.105
It  does  thus  apply  to  databases  in  any  form,106 but  does not 
apply to the software used in the making or operation of the 
database or to the works and materials contained therein.107
Nor does it affect the legal provisions covering patents, marks, 
designs and models or unfair competition that can apply to the 
database or to its contents.
103  Directive  96/9/EC  of  the  European  Parliament  and  the  Council  of  11  March  1996  on  the  legal 
protection of databases, OJ. L77, of 27 March 1996, 20-28.
104  See infra for a definition of this concept.
105  Directive 96/9 on the legal protection of databases, art. 1, 2.
106  Directive 96/9 on the legal protection of databases, art. 1, 1.
107  Directive 96/9 on the legal protection of databases, art. 1, 3.
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10.1.1.2.Copyright protection
Copyright can be defined as a free and automatic  protection 
that  is  granted without  any  formality  on literary and artistic 
works,  which  include  amongst  others,  any  production  in  the 
scientific  domain.108 Copyright  is  thus  only  granted  to  works 
that are expressed in a certain form and are original. 
Copyright thus only applies to the structure of databases, but 
not to their contents. The article 3, 2, of the Directive foresees 
it moreover very specifically.
The protection of the scheme of a database under copyright law 
as defined by the Agreement on TRIPS is thus accorded when 
the scheme constitutes, by virtue of the choice or arrangement 
of the material, an intellectual creation particular to its author. 
In other words, one can say that copyright protection is granted 
to  ‘original’  database  as  they  are  to  a  certain  extend  the 
expression of their authors’ personality.109
A database of electronic health records could then be capable of 
being copyrighted,  given that the healthcare practitioner has 
completed the records in an elaborate and original way. 
This could also be the case for genetic110 or tissue databases. 
Copyright protection could apply to the database comprised of 
tissue  samples  once  the  tissue  data  were  coordinated  and 
arranged in an original structure that could for instance help 
researchers.
The creator or the author of the database enjoys a group of 
exclusive  rights.  He  shall  indeed  have  the  exclusive  right  to 
carry out or to authorise:
108  Definition proposed in “Intellectual property on medical data chimaeras and actuality”, opcit, p. 747.
109  On the  contrary,  a  “non-original”  database  can be defined  as  a  structure  which  does  not,  in  its 
arrangement,  reflect  choices  of  the  creator,  but  in  which  this  mast  one  has  made  substantial 
investment.
110  For a detailed analysis of copyright protection for genetic databases in the United States see, Ray K. 
HARRIS and Susan Stone ROSENFIELD, “Copyright Protection for Genetic Databases”, 45 Jurimetrics, 
2005, p. 225-250.
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(a) temporary or permanent reproduction by any means 
and in any form, in whole or in part;
(b) translation, adaptation, arrangement and any other 
alteration;
(c) any  form  of  distribution  to  the  public  of  the 
database or of copies thereof. The first sale in the 
Community of a copy of the database by the right 
holder or with his consent shall exhaust the right to 
control resale of that copy within the Community;
(d) any communication, display or performance to the 
public;
(e) any  reproduction,  distribution,  communication, 
display or performance to the public of the results 
of the acts referred to in (b).111
Though there are exceptions to this rule. Indeed, the legitimate 
user of a database may perform all the acts referred to in article 
5 of the Directive that are necessary for using the database. 
On the other hand, Member States have the option of providing 
for limitations on the rights set out in article 5 in some specific 
circumstances  such  as  when  the  database  is  used  for  the 
purposes of public security or of an administrative or judicial 
procedure.112
However, the protection granted to databases by Directive 96/9 
might  seem  insignificant  with  the  efforts  and  the  energy 
demonstrated by data grids creators in other to retrieve in each 
case,  molecular,  cellular,  tissue  or  personal  data.  Only  the 
structure of these databases is protected, while value for sure 
still resides in the samples of the databases for development of 
enhancements, competing technologies or follow-on products.
That is certainly the reason why in addition to the copyright 
arrangements, provision has also been made for  “sui generis” 
protection.
111  Directive 96/9 on the legal protection of databases, art. 5.
112  For details on this point see Directive 96/9 on the legal protection of databases, art. 6.
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10.1.1.3.Sui generis protection
The Directive 96/9 introduced another protection for databases 
beside copyright. It created a new exclusive  sui generis right 
for database producers.
Sui  generis rights  protect  the  substantial  investment  of  the 
database  producer  from  a  quantitative  and  qualitative 
perspective, in the obtaining, verification or presentation of the 
contents of the database.113
There is thus a different protection granted for any investment 
made (financial  and in terms of  human resources,  effort  and 
energy)  in  the  obtaining,  verification  or  presentation  of  the 
contents of a database. 
So, in terms of protection granted, the difference between the 
structure,  the  content  and  the  investment  made  for  the 
development  of  a  database  is  very  important.  Copyrights 
protect  the  structure  of  databases,  while  sui  generis rights 
protect the investment made for the development of databases. 
The contents of these databases are sometimes protected as for 
them by intellectual property rights or by other types of legal 
protection.114
In the framework of the sui generis protection, the creator of a 
database (i.e. the person who made the investment), whether a 
natural or a legal person can prohibit the unauthorised retrieval 
and/or re-use of its contents.115 Protection against unauthorised 
retrieval or re-use is accorded to databases whose maker is a 
113  Directive 96/9 on the legal protection of databases, art. 7, 1. See also recitals 40 to 42 of the Directive.
114  On this point, see point B infra.
115  Directive 96/9 on the legal protection of databases, art. 7, 1. The terms extraction and re-utilisation 
are defined in article 7, 2 of the Directive. In this framework, extraction shall be seen as the permanent 
or temporary transfer of all or of a substantial part of the contents of a database to another medium by 
any means or in any other form. On the other hand, re-utilisation shall  mean any form of making 
available to the public all or a substantial part of the contents of a database by the distribution of 
copies, by renting, by on-line or other forms of transmission. The first sale of a copy of a database 
within the Community by the right holder or with his consent shall exhaust the right to control resale 
of that copy within the Community.
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national,  a  company or an undertaking resident  in or having 
his/its  registered  office,  central  administration  or  principal 
place of business in the Community.
On the contrary and as underlined by researchers Laura Vilches 
Armesto and Philippe Laurent “non-substantial extractions and 
reuses may be undertaken by third parties, without the right 
owner’s authorisation, as long as these acts are not made in a 
repeated and systematic way that would imply a conflict with 
the  normal  exploitation  of  the  database  or  produce  an 
unreasonable  prejudice  to  the  legitimate  interests  of  the 
database’s maker”.116
The  fact  that  non-substantial  parts  of  a  database  may  be 
extracted from it and re-used in another database might cause a 
prejudice  to  other  interests  than  the  ones  of  the  database 
creator.
For  instance,  the  extraction  of  information  from  a  database 
containing medical records might cause a prejudice to patients’ 
rights. There can thus be a contradiction between this right to 
re-use  non-substantial  parts  of  a  database  to  create  another 
database  for  example  and  the  legislation  applicable  to  the 
protection of  the data  which requires  for  any re-use  of  data 
relative to a patient, the agreement of this one.
Furthermore, on this topic it is important to underline that sui 
generis rights  form  pecuniary  rights  and  as  such  can  be 
transferred, assigned or granted under contractual licence.117
This  principle  applies  irrespective  of  the  eligibility  of  the 
database  for  protection  by  copyright  or  by  other  rights. 
Moreover, it applies irrespective of eligibility of the contents of 
that  database  for  protection  by  copyright  or  by  other  rights 
such as patient’s rights.118
116  Directive 96/9 on the legal protection of databases, art. 7, 5, a contrario. 
117  Directive 96/9 on the legal protection of databases, art. 7, 3.
118  Directive 96/9 on the legal protection of databases, art. 7, 4.
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Finally, it is also important to mention that the right to prevent 
the unauthorised retrieval of the contents of a database extends 
for a period of 15 years with effect from the date on which the 
creation of the database was terminated.119
The combination of these two principles, i.e.  sui generis rights 
form  pecuniary  right  and  sui  generis  protection  lasts  for  a 
period  of  15  years,  may  constitute  an  impediment  for  the 
deployment of Healthgrids.
Database  creators  could  for  example  charge  third  parties 
wanting to develop data grids before granting them their  sui 
generis rights under contractual licence. They might thus be an 
impediment  in  terms  of  costs  to  the  implementation  of 
Healthgrids. On the other hand, in the pharmaceutical sector, 
researchers might claim sui generis rights on certain databases. 
Such claims could delay the release of other products that could 
have been discovered on the basis of the information contained 
in the first database compiled in another way.
By introducing the  sui generis protection, the purpose of the 
European  Commission  was  to  induce  an  increase  in  the 
European database industry’s rate of growth and in database 
production. The Commission (DG Internal Market and Services) 
published  on  12  December  2005,  the  first  evaluation  of  its 
directive. This evaluation also looks at whether the scope of the 
right  targets  those  areas  where  Europe  needs  to  encourage 
innovation.
The evaluation was conducted on the basis  of  a  2005 online 
survey addressed to the European database industry and of the 
119  Directive 96/9 on the legal protection of databases, art. 10, 1. In the case of a database which is made 
available to the public in whatever manner before expiry of the period provided for in paragraph 1 of 
article 10,the term of protection by that right shall expire fifteen years from the first January of the 
year following the date when the database was first made available to the public (art. 10, 3). Finally 
any  substantial  change,  evaluated  qualitatively  or  quantitatively,  to  the  contents  of  a  database, 
including any substantial change resulting from the accumulation of successive additions, deletions or 
alterations, which would result in the database being considered to be a substantial new investment, 
evaluated qualitatively or quantitatively, shall qualify the database resulting from that investment for 
its own term of protection (art. 10, 3).
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Gale Directory of Databases (the “GDD”), which is the largest 
existing database directory.
Indeed, the vague terms used in the Directive to define the sui 
generis right  seem  to  have  caused  considerable  legal 
uncertainty. Also the scope of the sui generis right was severely 
curtailed in a series of  judgments rendered by the European 
Court of Justice in November 2004.120
On  publication,  DG  Internal  Market  and  Services  invited 
stakeholders  to  comment  on  four  options:  repeal  the  whole 
directive  (option  1);  withdraw  the  sui  generis right  while 
leaving protection for creative databases unchanged (option 2); 
amend the sui generis provisions in order to clarify their scope 
(option 3); maintain the status quo (option 4).121 
In  that  context,  Internal  Market  and  Services  Commissioner 
Charlie Mc Creevy said: 
“Databases  are  a  key  part  of  Europe’s  economy  in  the 
information age. I want to make sure that EU rules encourage 
database production, not hinder it. This evaluation puts us on 
the  right  track.  I  now  call  on  the  industry  and  other 
stakeholders  to  comment  and  tell  us  more  about  how  EU 
database rules affect them”.
The open consultation will be concluded with a final assessment 
by the Commission on whether legislative changes are needed 
or not. 
Whatever  is  the  decision  of  the  Commission,  it  will  change 
nothing to the contradiction which can exist between copyrights 
and patients’ rights (B).
120  The ECJ’s differentiation between the resources used in the creation of the contents of a database and 
the obtaining of such data in order to assemble a database demonstrate that the new right comes 
precariously close to protecting basic information.
121  Public  consultation  was initially  open until  12 March 2006,  but  extended to  31 March 2006.  55 
contributions were received.
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10.1.2.Part I: B: Copyrights and Patients’ Rights 
As evoked  earlier  in  point  A  of  this  Chapter,  copyrights  can 
oppose patient’s rights.
Indeed,  a  database  author  has  the  right  to  control  the 
reproduction and the communication of his work to the public. 
But  in the case of  databases constituted of  electronic  health 
records, cellular or tissues, the work is “[…] created with data 
relating  to  patient(s),  (their)  bodies,  (their)  health  and  the 
treatment they undergo. These data (are) subject to very strict 
sensitive data protection and privacy rules”.122
Some authors and researchers think that the patient’s  rights 
and  the  protection  of  sensitive  data  have  to  dominate  on 
copyright. This would have a direct impact on the exercise of 
authors’  exclusive  rights.  For  instance,  an  author  could  not 
anymore exercise his exclusive rights alone.
If  it  is  desirable  that  copyrights  on  databases  composed  of 
medical  data,  genetic  data  and  other  materials  relating  to 
patients, should never distorts patients’ rights, taking the path 
described above  could  impede the  development  of  databases 
and as a consequence the development of Healthgrids.
Indeed, if there were only rare cases where an author can claim 
copyrights on his work, nobody would be willing to make the 
investment necessary for the creation of a database.
One of the possible solutions would be to introduce a distinction 
between various types of data, as the medical data and the data 
of health or sanitary data. 
In the case of electronic health records, it would be advisable 
among others to determine the status of the personal notes of 
the doctor. Indeed most of the blockings seem to come from the 
122  “Intellectual property on medical data chimaeras and actuality”, opcit, p. 748.
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absence of clear and precise definition of the notion of medical 
datum.123
Finally, it is important to underline that if copyrights are a sort 
of reward (at least a financial one) for the creators of databases, 
they also constitute a brake in the development of Healthgrids 
(II).
10.2.PART II: INTELLECTUAL PROPERTY RIGHTS AND 
GRIDS’ COMPONENTS 
On  27  July  1995,  the  European  Commission  issued  a  green 
paper  on  copyright  and  related  rights  in  the  information 
society.124 The purpose of this green paper was to set out the 
background to a number of questions of copyright and related 
rights as the information society was developing. 
In his first part, the paper thus described how the information 
society was ought to function and highlighted the issues that 
arise as a result of the emergence of that society. The second 
part  of the paper picked out nine points regarding copyright 
and related rights that the Commission believes should be given 
priority in order to ensure that the information society could 
function properly.
Indeed,  in that time,  the Commission believed that  copyright 
and related rights could provide an incentive for the creation of 
and investment in new works and other protected matter and 
their  exploitation,  thereby  would  contribute  to  improved 
competitiveness,  employment  and  innovation.  Latter,  this 
proved to be true.
But  in  that  time,  even  if  the  information  society  could  start 
developing  on  the  basis  of  Directive  91/250  on  the  legal 
protection of computer programs (A),  the legal  framework of 
123  Philippe VANLANGENDONCK,  « Le  dossier  médical  électronique :  problèmes de vie  privée et  de 
responsabilité », sur http://www.droit-technologie.org, p. 1-10. For developments on this topic see the 
Roadmap document. 
124  COM(95)382, not published in the Official Journal. 
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the European Union was not yet ready for the deployment of 
vast  networks. Indeed,  owing  to  the  very  nature  of  such 
networks, any wide variation in the level of protection of works 
and other protected matter may place obstacles in the way of 
their development.
A  Community-wide  harmonisation  of  the  national  legislations 
available  for  the  protection  of  copyright  and  certain  related 
rights  mainly took place in the shape of two directives (B and 
C). This legal framework was completed with the Directive on 
the legal protection of databases mentioned above.
With  all  theses  measures,  the  Community  seemed  to  have 
provided  a  proper  legal  framework  for  the  development  of 
services in the information society.
What about the development of Healthgrids on a European-wide 
basis?
It  seems  that  the  legal  framework  developed  within  the 
European Union allows a  harmonised protection of  copyright 
and related rights in all the EU Member States. In this sense, 
the  harmonisation  of  the  national  legislation  will  favour  the 
implementation of Healthgrids as services can circulated freely 
without any barriers and that market will not be fragmented.
On the other hand, copyrights can constitute an impediment in 
the  implementation  of  Healthgrids,  given  that  copyright  law 
treats computer software as a copyrightable literary work, the 
same  as  a  play  or  a  novel.  The  copyright  owner  has  the 
exclusive  rights  to  reproduce  his  work,  prepare  derivative 
works, distribute copies to the public, perform the work publicly 
and display the work publicly. Under these circumstances any 
natural  or  legal  person  would  have  to  pay  to  use  computer 
programs  while  they  constitute  one  of  the  most  important 
compound of Healthgrids.
The open source software approach could then be a solution to 
help the development and implementation of Healthgrids. In the 
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United States, the open source model actually uses copyright 
and contract principles to retain control of the work and could 
thus encourage use without dedicating the work to the public 
domain.125
But for the moment let us analyse at first the legal framework in 
which the systems elaborate.
10.2.1.Part II: A: Directive 91/250 on the legal protection 
of computer programmes126 
The Directive on the legal protection of computer programs was 
a  real  European  'first'  for  copyright  law,  the  first  copyright 
measure to be adopted following the publication of the White 
Paper on completing the Single Market by 1992. 
The objective of the Directive was to harmonise Member States’ 
legislation regarding the protection of computer programmes in 
order to create a legal environment that will afford a degree of 
security  against  unauthorised  reproduction  of  such 
programmes.
10.2.1.1.Protection’s subject matter
In  accordance  with  the  Directive’s  provisions,  the  Member 
States are obliged to protect computer programs, by copyright, 
as literary works within the meaning of the Berne Convention 
for the Protection of Literary and Artistic Works.127
The  ideas  and  principles  that  underlie  any  element  of  a 
computer program, including those that underlie its interfaces, 
are not protected by copyright.128
125  See Dennis M. KENNEDY, “A primer on open source licensing legal issues: copyright, copyleft and 
copyfuture,  20  ST.  LOUIS  U.  PUB.  L.  REV.,  2001,  345,  p.  359-360;  David  MCGOWAN,  “Legal 
implications of open-source software”, U. ILL. L. REV., 2001, 241, p.242-243. More generally see Open 
Source Initiative, at http://www.opensource.org.
126  Council Directive 91/250/EEC of 14 May 1991 on the legal protection of computer programs,  O.J.  L 
122, of 17 May 1991, 42–46.
127  Directive 91/250 on the legal protection of computer programs, art. 1, 1.
128  Directive 91/250 on the legal protection of computer programs, art. 1, 2.
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A computer program shall be protected if it is original in the 
sense that it is the author’s own intellectual creation. No other 
criteria  shall  be  applied  to  determine  its  eligibility  for 
protection.129
10.2.1.2.Authorship of a computer programme
In general, the author of a computer program is the natural or 
legal person or group of natural persons who created it. 
Where collective works are recognised by the legislation of a 
Member State, the person considered by the legislation of that 
Member State to have created the work is  deemed to be its 
author.130 
In the case of a program created by a group of natural persons, 
the exclusive rights are owned jointly.131 
Finally, the Directive also provided for the situation of copyright 
ownership of work for hire. Indeed, where a computer program 
is  created  by  an  employee  in  the  execution  of  his  duties  or 
following the instructions given by his employer, the employer 
alone  will  be  entitled  to  exercise  all  economic  rights  in  the 
program, unless otherwise provided for by contract.132 
Protection is accorded on the basis of residence, nationality and 
first publication as laid down by the relevant Member State.
10.2.1.3.Copyright protection
Subject to the provisions of Articles 5 and 6 of the Directive, the 
exclusive rights of the author of a computer program include 
the right to perform or to authorise:
129  Directive 91/250 on the legal protection of computer programs, art. 1, 3.
130  Directive 91/250 on the legal protection of computer programs, art. 2, 1.
131  Directive 91/250 on the legal protection of computer programs, art. 2, 2.
132  Directive 91/250 on the legal protection of computer programs, art. 2, 3.
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(a)the  permanent  or  temporary  reproduction  of  his 
computer program by any means and in any form, in 
part or in whole;133 
(b)the  translation,  adaptation,  arrangement  and  other 
alteration  of  his  computer  program  and  the 
reproduction of the results thereof without prejudice to 
the rights of the persons who alters the program; 
(c) the  distribution,  including  the  rental,  of  his  original 
computer program or of copies thereof.134 
10.2.1.4.Exceptions to the protection granted
The  Directive  provides  for  certain  exceptions  regarding 
copyright, mainly in the situations described below.
The making of a back-up copy by a person having a right to use 
the  computer  program  may  not  be  prevented  by  contract 
insofar as it is necessary for that use.135 
Equally, a person having a right to use a copy of a computer 
program is entitled to observe, study or test the functioning of 
the  program in  order  to  determine  the  ideas  and  principles 
which underlie any element of the program if he does so while 
performing  any  of  the  acts  of  loading,  displaying,  running, 
transmitting  or  storing  the  program  which  he  is  entitled  to 
perform.136
There is also provision for a derogation that would allow the 
decompilation137 of a program under certain limited conditions 
133  Insofar as loading, displaying, running, transmission or storage of the computer program necessitate 
such reproduction, such acts shall be subject to authorisation by the author of the program.
134  On this point, it  is important to underline,  what the Directive also does, that the first sale in the 
Community of  a copy of  a computer program by the right holder or with his consent exhaust  the 
distribution right within the Community of that copy, with the exception of the right to control further 
rental or the program or copy thereof.
135  Directive 91/250 on the legal protection of computer programs, art. 5, 2.
136  Directive 91/250 on the legal protection of computer programs, art. 5, 3.
137  Decompilation  can  be  defined  as  reproducing  the  code  source  of  the  computer  program  and 
translating its form in order to obtain the information necessary to achieve the interoperability of an 
independently created program with other programs.
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and  with  the  aim  of  achieving  the  interoperability  of  an 
independently created computer program.138
10.2.1.5.Special protection measures
Special  protection  measures  will  be  taken  against  a  person 
committing any of the acts listed hereunder:
(a) any act of putting into circulation a copy of a computer 
program knowing, or having reason to believe, that it is a 
pirated copy; 
(b) any possession for  commercial  purposes  of  a  copy of  a 
computer program knowing, or having reason to believe, 
that it is a pirated copy; 
(c) any act of putting into circulation or the possession for 
commercial  purposes  of  any  means  with  the  intended 
purpose  of  facilitating  the  unauthorised  removal  or 
circumvention  of  any  technical  device  which  may  have 
been applied to protect a computer program.
These special protection measures shall be provide for by the 
Member  States,  each  one  in  accordance  with  its  national 
legislation, by virtue of Article 7, 1, of the Directive.
10.2.1.6.Terms of protection
Protection shall be granted for the life of the author and for fifty 
years after  his death or after  the death of  the last  surviving 
author.
On the other hand, the term of protection is fifty years from the 
time the computer program is first made available to the public 
when the computer program is  an anonymous work,  when it 
was made available to the public under a pseudonym or when a 
legal person is designated as the author.
138  For more details on this point, see Directive 91/250 on the legal protection of computer programs, art. 
6.
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The Directive  93/98 on harmonising the term of protection of 
copyright and certain related rights, mentioned below, extended 
the duration of copyright protection to seventy years.
10.2.1.7.Directive’s evaluation
On 10 April 2000, the European Commission addressed a report 
to the Council, the European Parliament and the Economic and 
Social  Committee  on  the  implementation  and  effects  of  the 
Directive.139 
This  report  contained an  evaluation  of  the  Directive’s 
implementation  in  the  Member  States.  It  showed  that  the 
Directive’s objectives had been achieved and that its effect on 
the  software  sector  had  been  satisfying.  The  Directive  had 
indeed improved the situation of the computer program sector 
in  four  ways:  piracy  was  reduced,  employment  increased,  a 
139  COM(2000)199 final.
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switch  had  been  operated  to  open  systems  together  with  a 
harmonisation as to computer programs created by employees. 
However,  the  Commission  stated  that  she  might  have  to 
examine certain imperfections in greater depth. In particular, 
some  specific  problems  had  been  raised  as  regards  the 
distribution  right  and  communication  to  the  public,  back-up 
copies,  remedies  and  the  technical  provisions  (i.e.  the  same 
problems  that  one  will  be  confronted  with  for  Healthgrids’ 
implementation).
10.2.2.Part  II:  B:  Directive  93/98  on  harmonising  the 
terms of protection of copyright and certain related 
rights
As mentioned above,  Directive (93/98/EEC)140 harmonised the 
terms of protection of copyright and neighbouring rights. The 
Directive  establishes  a  total  harmonisation  of  the  period  of 
protection for each type of work and each related right in the 
Member States -e.g. 70 years after the death of the author for 
works and 50 years after the event setting the time running for 
neighbouring  rights.  Furthermore,  it  dealt  with  other  issues, 
such  as  the  protection  of  previously  unpublished  works,  of 
critical and scientific publications and of photographic works.
The  Directive  sets  the  duration  of  copyright  in  a  literary  or 
artistic work at 70 years after:
(a) the death of the author of the work141 or
(b) the  date  on  which  the  work  was  lawfully  made 
available to the public, in the case of an anonymous or 
pseudonymous work.142
It sets the term of protection for cinematographic or audiovisual 
works at 70 years after the death of the last of the following 
persons to survive, i.e. the principal director, the author of the 
140  Council Directive 93/98/EEC of 29 October 1993 on harmonising the term of protection of copyright 
and certain related rights, O.J. L290, of 24 November 1993, 9-13.
141  Directive 93/98/EEC, art. 1, 1.
142  Directive 93/98/EEC, art. 1, 3.
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screenplay,  the  author  of  the  dialogue  and  the  composer  of 
music  specifically  created  for  use  in  the  cinematographic  or 
audiovisual work.
On the other hand, it  sets  the term of  protection for related 
rights at 50 years. 
The terms laid down in the Directive are calculated according to 
the circumstances, from the date of the performance, the date 
of the publication or communication of the fixation, or the date 
of the broadcast. 
But the interesting point is that the term of protection starts to 
run at the same time in every Member State. It is calculated 
from the first day of January of the year following the event 
which gives rise to it.143 In this framework, when the work is 
originated  in  a  third  country  or  when  the  author  is  not  a 
Community  national,  the  protection  granted  by  the  Member 
States expires on the same date as the protection granted in the 
country of origin of the work, but must never exceed the term 
laid down in the Community.
Finally,  the  Directive  provides  that  the  Member  States  are 
required to notify the Commission immediately of any plan to 
grant new related rights. They are also required to bring into 
force  the  laws,  regulations  and  administrative  provisions 
necessary to comply with the Directive.
An enormous work of harmonisation of the national legislation 
on  the  protection  of  copyright  and  related  rights  was  thus 
achieved through Directive 93/98. The work continued in the 
direction  of  an  adaptation  of  the  member  States  national 
legislation  performed  by  Directive  2001/29  on  the 
harmonisation of certain aspects of copyright and related rights 
in the information society.
143  Directive 93/98/EEC, art. 8.
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10.2.3.Part II: C: Directive 2001/29 on the harmonisation 
of certain aspects of copyright and related rights in 
the information society144
This  Directive  aimed  to  adapt  legislation  on  copyright  and 
related rights to technological developments and particularly to 
the  information  society.  The  objective  was  to  transpose  at 
Community  level  the  main  international  obligations  deriving 
from two Treaties145 concerning copyright and related rights, 
adopted  in  December  1996  in  the  framework  of  the  World 
Intellectual Property Organisation (also named ‘WIPO’).
10.2.3.1.Directive’s scope
Unless  otherwise  provided,  the  Directive  applies  without 
prejudice to existing provisions relating to the legal protection 
of  computer programs,  rental  and lending rights  and certain 
rights related to copyright in the field of intellectual property, 
copyright  and  related  rights  applicable  to  broadcasting  of 
programmes by satellite and cable retransmission, the term of 
protection of copyright and certain related rights and the legal 
protection of databases.146
The  aim  of  the  Directive  was  also  to  deal  with  three  main 
issues, i.e. reproduction rights, the right of communication and 
distribution rights.
Indeed, as regards the first issue, the Directive should define 
the scope of the acts covered by the reproduction right with 
regard to  the  different  beneficiaries.  This  should  be  done in 
conformity with the  acquis communautaire. A broad definition 
of these acts was indeed needed to ensure legal certainty within 
the internal market.147
144  European Parliament  and Council  Directive 2001/29/EC of  22 May 2001 on the harmonisation of 
certain aspects of copyright and related rights in the information society, O.J. L 167, of 22 June 2001, 
10-19.
145  These two Treaties were the  WIPO Copyright Treaty and the WIPO Performances and Phonograms 
Treaty.
146  Directive 2001/29/EC, recital 20.
147  Directive 2001/29/EC, recital 21.
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The Directive thus concerns the legal  protection of copyright 
and related rights in the framework of the internal market, with 
particular emphasis on the information society.148 Moral rights 
remain outside the scope of the Directive.149
10.2.3.2.Reproduction rights
Under Article 2 of the Directive, Member States are to provide 
for the exclusive right to authorise or prohibit direct or indirect, 
temporary or permanent reproduction by any means and in any 
form, in whole or in part:
(a) for authors, of the original and copies of their works;
(b) for performers, of fixations of their performances;
(c) for phonogram producers, of their phonograms;
(d) for the producers of the first fixation of films, in respect 
of the original and copies of their films;
(e) for  broadcasting  organisations,  of  fixations  of  their 
broadcasts, whether those broadcasts are transmitted by 
wire or over the air, including by cable or satellite. 
10.2.3.3.Right of communication
Moreover,  by  virtue of  Article  3,  1  of  the Directive,  Member 
States  are  to  provide  authors  with  the  exclusive  right  to 
authorise or prohibit  any communication to the public of the 
originals  and  copies  of  their  works,  including  the  making 
available  to  the  public  of  their  works  in  such  a  way  that 
members of the public may access them from a place and at a 
time individually chosen by them.
The same applies as regards the making available to the public 
of protected works in such a way that members of the public 
may access them from a place and at a time individually chosen 
by them:
(a) for performers, of fixations of their performances, 
(b) for phonogram producers, of their phonograms, 
148  Directive 2001/29/EC, art. 1.1.
149  Directive 2001/29/EC, recital 19.
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(c) for  the  producers  of  the  first  fixation  of  films,  in 
respect of the original and copies of their films, 
(d) for  broadcasting  organisations,  of  fixations  of  their 
broadcasts - regardless of the method of transmission. 
10.2.3.4.Distribution rights
Finally, the Directive harmonised for authors the exclusive right 
of distribution to the public of their works or copies thereof. 
This distribution right is exhausted where the first sale or other 
transfer of ownership in the Community of a copy is made by 
the right holder or with his consent.150 
10.2.3.5.Exemptions and limitations
The Directive also laid down a number of exceptions to the right 
of reproduction and the right of communication in his Article 5.
There was to begin with, a mandatory exception to the right of 
reproduction.  This  exception  was  introduced  in  respect  of 
certain temporary acts of reproduction which are integral to a 
technological process, the purpose of which was to enable the 
lawful use or transmission in a network between third parties 
by an intermediary of a work or other subject-matter and which 
has no separate economic significance.
The  Directive  also  contained  a  provision  for  other  non-
mandatory  exceptions  to  the  rights  of  reproduction  or 
communication. In these cases, they are accorded at national 
level by the Member State concerned.
10.2.3.6.Rights of reproduction and communication
In  the  Directive’s  framework,  the exemptions  and limitations 
relating to the rights of reproduction and communication are 
optional and particularly concern the “public” domain. 
150  Directive 2001/29/EC, art. 4.
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For  three  of  these  exceptions  -reprography,  private  use  and 
broadcasts made by social institutions- the right holders are to 
receive fair compensation.
With  regard  to  the  exceptions  or  limitations  to  distribution 
rights, these are accorded depending on the exceptions relating 
to reproduction or communication.
10.2.3.7.Protection of technological measures151
The  Member  States  were  equally  obliged  to  provide  legal 
protection  against  the  circumvention  of  any  effective 
technological measures152 covering works or any other subject 
matter.  This  legal  protection  also  related  and  still  does  to 
“preparatory  acts”  such  as  the  manufacture,  import, 
distribution, sale or provision of services for works with limited 
uses. 
Nevertheless,  for  some  exceptions  and  limitations,  in  the 
absence  of  voluntary  measures  taken  by  right  holders,  the 
Member  States  had  to  ensure  the  implementation  of  an 
exception or limitation for those who may benefit from it. The 
Member States had also the choice to take such measures with 
regard to the exception for private use, unless right holders, in 
accordance with the economic damage test, had already made 
reproduction for private use possible.
151  Directive 2001/29/EC, art. 6.
152  For the purposes of the Directive, the expression “technological measures” means any technology, 
device or component that, in the normal course of its operation, is designed to prevent or restrict acts, 
in  respect  of  works or other  subject-matter,  which  are  not  authorised  by  the  right  holder  of  any 
copyright  or  any related to  copyright  as  provided for  by law or sui  generis  right  provided for  in 
Chapter II of Directive 96/9/EC. 
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10.2.3.8.Protection of rights-management information153
Finally  Member  States  had  to  provide  for  adequate  legal 
protection against  any person knowingly  performing,  without 
authority, any of the following acts:
(a) the  removal  or  alteration  of  any  electronic  rights-
management information; 
(b) the  distribution,  importation  for  distribution, 
broadcasting,  communication  or  making  available  to 
the public of works or other subject-matter protected 
from which electronic rights-management information 
has been removed or altered without authority.
153  Directive 2001/29/EC, art. 7. For the purposes of the Directive, the expression “right-management 
information” means any information provided by the right holders which identifies the work and other 
subject-matter referred to in this Directive or covered by the sui generis right provided for in Chapter 
III  of  Directive  96/9/EC,  the  author  or  any other  right  holder,  or  information  abut  the  terms and 
conditions of use of the work or other subject-matter, and any numbers or codes that represent such 
information.
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